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ABSTRACT 		 	In order to elucidate the biological processes that occur in everyday life, chemical 
biologists have developed technologies that allow the study of a various biological 
systems. Bioorthogonal chemistry is an ever-growing technology that involves 
performing chemical reactions with biological systems that do not rely on existing 
biological chemistries. In this work we attempt to develop and characterize novel 
bioorthognal chemistries that further expand the utility of this field. Additionally, we 
explore the utility of fluorescent probes in labeling applications. Finally, we attempt to 
create novel methods of control for a gene-editing protein using light as a mechanism of 
regulation.	
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CHAPTER 1: INTRODUCTION TO UNNATURAL AMINO ACIDS AND 
BIOCONJUGATIONS 	
 
Proteins are a class of essential macromolecules that perform a multitude of 
functions necessary within the cells of all living organisms.1, 2 These functions include 
catalyzing chemical reactions, transporting various molecules, providing a means of 
communication throughout the body, and as structural support for cells. Proteins are 
composed of various combinations of twenty naturally occurring amino acids. The 
information to form the sequence of amino acids of a protein is stored within the DNA 
sequence within the organism’s genome. This DNA is first transcribed into mRNA, 
which is then translated into protein (Figure 1).  
 
 			
 
 
 
 
 
 
 
 
 
 
 
Figure 1. The central dogma, the process of converting genetic information in to 
functional protein. Adapted from Nat. Rev. Genet. 2002 3, 43-52.3  
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Translation occurs on the ribosome, where three base pair segments of the 
mRNA, called codons, are used to encode a single amino acid. Codons on the mRNA are 
recognized by anticodons on tRNA molecules.  Each tRNA has a corresponding amino 
acid that is bound to it through aminoacylation, by an aminoacyl tRNA synthetase (aaRS) 
enzyme, refer to figure 2.1 The tRNA charged with an amino acid is then used by the 
ribosome to form new peptide bonds between amino acids. This process repeats itself 
multiple times to biosynthetically prepare proteins. The primary sequence of amino acids 
affords intramolecular interactions to form secondary and tertiary structures, as well as 
quaternary structures with other polypeptide chains. Once properly assembled, these 
proteins are then able to perform various tasks within the cell.  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2. Comparison of natural translation and translation using unnatural amino 
acids and a mutated tRNA synthetase. Adapted from Chem. Biol. 2009 16, 323-
336.4 
 
The diversity of the polypeptide sequences and structures allows for various 
functions; however, there are limitations due to the limited chemical functionality of the 
natural 20 amino acids. The canonical amino acids are made of only five elements that 
create acidic, basic, polar, and hydrophobic residues.  Incorporation of unnatural amino 
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acids (UAAs) into a protein can introduce a multitude of unique chemical functionalities 
that may expand the function of a protein. These amino acids can also be inserted into 
proteins and manipulated to facilitate the study of the protein structure and function.1, 2 
UAAs also have many clinical applications including: labeling HER2 cancer cells 
with fluorescent markers5, selectively binding cytotoxic cancer drugs to antibodies to 
provide better specificity6, and artificially stimulating immune systems.2 With these 
diseases affecting such a large portion of our population, working to perfect and expand 
this methodology represents a mechanism to introduce new therapeutics and diagnostics. 
Moreover, there has been recent work that employed UAAs for work in synthetic 
biology.7 Synthetic biology is a field of biology that creates new tools to help solve 
biological problems or create new ways to better study biological phenomena. The use of 
UAAs in these capacities indicates a bright future for advancement with this technology. 
1.I.  UNNATURAL AMINO ACIDS AND INCORPORATION 
There are approximately 70 UAAs that have been synthesized and incorporated 
into proteins. The diversity of the chemical functionalities of the UAAs affords a myriad 
of novel protein functions (Figure 1).1, 2 These amino acids have functionalities that are, 
for the most part, non-disruptive to the necessary functions of the cell, but confer new 
chemical properties to the protein to facilitate unique functions. 
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Figure 3. Structures of unnatural amino acids previously synthesized and incorporated.  
 
To incorporate these UAAs into protein an orthogonal aminoacyl tRNA 
synthetase (aaRS) is required to aminoacylate the unnatural amino acid to a nonsense 
suppressor tRNA.1, 2, 8 This represents a bioorthogonal aaRS/tRNA pair that does not 
cross-react with any of endogenous translational system. The incorporation of 
aaRS/tRNA from an archaebacteria species into E. coli though allows for adequate 
functionality for translation within the organism without negatively interacting with 
endogenous aaRS/tRNA. Additionally, the amber stop codon is typically employed, as it 
is the least commonly used stop codon in E. coli.1 Often, a tyrosine aaRS and mutated 
amber tRNA from the archaea Methanocaldococcus jannaschii is used to allow E. coli 
incorporate UAAs. Other archaebacteria aaRS/tRNA have also been used with efficiency 
similar to that of Methanocaldococcus jannaschii, for example, a pyrrolysine pair derived 
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from the achaebacterium Pyrococcus horikoshii, has also been developed by Santoro et 
al.9 The ability to exploit different amino acid precursors provides a greater diversity in 
UAAs that can be manipulated, and ultimately incorporated into proteins. 
Liu et al. have also worked to improve the efficiency of the aminoacylation and 
translation of the mutant tRNAs.10 In addition to mutagenizing the anti-codon, 
modifications to other residues of the tRNA were also conducted. Mutations within the 
acceptor arm, the D-loop, and the anti-codon binding loop were performed to find the 
optimal translation with UAAs. 
To allow the tyrosyl-M. jannaschii tRNA (MjtRNATyr) recognize the TAG codon, 
the tRNA anti-codon is mutated to CUA.1, 2, 8 To selectively alter the M. jannaschii aaRS 
(MjTyrRS) to aminoacylate a UAA instead of the natural tyrosine, a library of mutant 
MjTyrRS are created and are evolved through a double-sieve selection procedure. Due to 
the inherent promiscuity of the active site within the aaRS selective pressure can be 
applied to the aaRS library to find specific aaRSs that recognize the desired UAA.11 The 
selection begins with a positive round as the aaRS library and tRNA are introduced into 
cells that contain a plasmid encoding a chloramphenicol resistance protein harboring a 
TAG mutation. The cells are then grown on media that has chloramphenicol in addition 
to the desired UAA. Consequently, only the surviving colonies will have been able to 
charge the UAA or an endogenous amino acid to provide antibiotic resistance. Cells 
possessing aaRSs that do not recognize the UAA result in a terminated chloramphenicol 
resistance protein, and consequently cannot survive. The plasmids from the positive hits 
are then isolated and subjected to a negative round of selection. The plasmids are 
transformed into cells containing a plasmid with a barnase gene posessing three amber 
stop codons. The barnase protein is cytotoxic as it is a bacterial ribonuclease, which will 
destroy bacterial RNA and will lead to the death of the cell if it is transcribed. These cells 
are grown in the absence of the UAA. Thus, if the cell is able to express barnase, the 
aaRS does incorporate amino acids at the stop codon, but it is not specific to the 
unnatural and can interact with the canonical amino acids. Since the barnase is present in 
the cells, the undesirable aaRSs are eliminated from the selection via the death of the cell. 
Therefore, the only cells that survive both rounds of selection possess an aaRS that only 
charges the UAA and not any of the 20 natural amino acids. The double selection process 
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is repeated multiple times to ensure the aaRS will charge the tRNA with the UAA with 
high specificity (Figure 4).  
                  
         
                                                         
Figure 4. The general procedure for double sieve selection for a functioning 
orthogonal mutant aaRS that will incorporate a specific Unnatural Amino Acid. 
 
These selective pressures promote the charging of an unnatural amino acid and 
not the charging of endogenous amino acids. However, there is no selective pressure for 
different UAAs to be charged to the tRNA. As a result, it remains possible that the 
evolved aaRS may be able to recognize and charge other UAAs that were not involved in 
the selection. This promiscuity can afford the incorporation of multiple UAAs by a single 
aaRS. 
In addition to being recognize by an aaRS and charged to the tRNA, the UAA 
must meet other requirements to afford its incorporation into a protein.2 For instance, the 
UAA must be permeable to the cell or readily synthesized by the cell. The UAA must 
also be compatible with all of the ribosomal machinery of the cell. These conditions are 
typically met when using prokaryotic organisms but issues have arisen when translating 
the technology to eukaryotic organisms. Consequently, yeast (a eukaryotic organism) 
have been exploited to incorporate UAAs with great success using similar methods as 
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employed with E. coli (Figure 2). More substantial problems exist when UAAs are 
integrated into other eukaryotic cell lines, like mammalian cell lines, due to 
complications with cell growth, the two-stage selection process and cell divisions.2, 12 
There has been some success though, by first manipulating yeast cells to incorporate 
UAAs and then transfecting mammalian cell lines with yeast DNA. Further improvement 
of eukaryotic expression still required making this approach more viable.  
Additionally, current research involves finding new methods to incorporate UAAs 
and to continue to improve the current methods. New archaebacterial aaRS/tRNA are 
being used in E. coli and new codons, other suppressor codons and four base codons, are 
being exploited to express multiple different UAAs in proteins.13 In order to increase 
protein yields, expression methods are being optimized as well.14 For instance, the 
plasmid vectors that are used to incorporate the genes to express the aaRS/tRNA were 
optimized with to be highly efficient, with the best promoters, ribosomal binding sites, 
and terminators. A plasmid vector called pEVOL was engineered, which provided the 
greatest protein yields and greatest stability for incorporation into E. coli. With these 
improvements UAA incorporation is continually developing into a much more 
manageable and useful technology.  
 
 
1. II. BIOORTHOGONAL CHEMISTRY 
 
One of the greatest advantages of employing unnatural amino acids is that it 
facilitates the incorporation of bioorthogonal functional groups. For an amino acid to be 
completely orthogonal it must not disturb the function of the protein, nor impede the 
other functions that occur within the cell.2 This is not to say that the residues that are 
incorporated are unreactive; however, they are only reactive with other introduced 
substrates. The introduced functionalites that undergo non-specific cross-reactions with 
the natural cellular processes are not completely orthogonal and can be detrimental to the 
organism. Interaction should be localized to the introduced functionalities and the 
reaction conditions that occur between them must also occur under physiological 
conditions, as deviation will also lead to biological damage.   
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This research focuses on the synthesis of UAAs possessing bioorthogonal handles 
that will facilitate novel chemistries within the cell. The functionalities can then react 
with tags or other molecules in a site-specific manner in a bioconjugation reaction to 
further modify the protein and its function. 
 With theses moieties (ketones/aldehydes, azides, alkynes, and alkenes) present in 
only specified proteins containing UAAs, reactions will only occur with the protein of 
interest.2 The unnatural functionalities must fulfill two essential criteria to function as 
efficient tools. First, the functional groups should not be able to interact with normal 
functions of the organism; only with other introduced functionalities. Second, the 
reactions must also occur in physiological conditions, as to minimize effects on the 
organism. Several reactions satisfy the first condition, but many reactions with UAAs do 
not meet the second condition, occurring outside of standard physiological conditions. 
Therefore, the development of new functionalities and reaction conditions is important to 
maximize the utility of bioconjugations in biological systems. Using these bioorthogonal 
reactions we can study processes in the cell like DNA replication, protein function, and 
glycosylation without disruption of the natural processes 
1.II.A. CLICK CHEMISTRY 
A commonly used bioconjugation reaction in our lab, was developed by Chan et 
al., involves a copper (I) catalyzed-1,3-dipolar cycloaddition, and is known as a “click 
reaction” (Scheme 1).  
Scheme 1. 
 
 
 
While this reaction is truly bioothogonal, as no naturally occurring alkynes or 
azides exist within proteins, it is challenging to perform in a truly in vivo setting.15 The 
reaction has a high reaction rate and high specificity, but high concentrations of copper 
within an organism are toxic.8, 15 Thus, a modified reaction has been developed using a 
strained cyclooctyne with fluorine substituents which performs the same dipolar 
R1 H + N3 R2
CuSO4
TBTA
TCEP
N
N N
R1
R2
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cycloaddtion with azides, but does not require the copper catalyst.16 This copper-free 
mechanism has comparable kinetics to the copper catalyzed reaction but is not cytotoxic. 
More reactions such as this one are needed to continue to allow for the cost of 
orthogonally. 
 
1.II.B. OXIME CHEMISTRY 
Oxime ligations are another form of bioconjugation involving the reaction of 
ketones or aldehydes with alkoxyamine groups (Scheme 2). This reaction is both 
bioorthogonal and can proceed in nearly physiological conditions. The reaction employs 
ketones and aldehydes to react with alkoxyamine compounds to form covalent oxime 
linkages (Figure 5).8, 17, 18  
 
Figure 5. The current non-specific antibody conjugation method. 
These alkoxyamines have enhanced reactivity due to the 𝛼 -effect, where 
substituents on the 𝛼-position of amines have a significant role on the nucleophilicity of 
the compound.19 Substituents contribute significantly to the alkoxyamine’s reactivity with 
an electrophile as they possess lone pairs of electrons that can contribute to a stabilized 
positive transition state. This reaction using an alkoxyamine functional group generates a 
stable covalent bond and can be useful in forming linkages with various molecular tools 
through interaction with aldehyde/ketone functionalities. For instance, recent work has 
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used oxime ligations to fluorescently label glycosylated cell surfaces that harboring 
exposed aldehyde functionalities.17 Cell surface glycans with sialic acid residues were 
modified to have aldehyde functionalities by periodate oxidation. Alkoxyamine 
functionalities on fluorescent probes could then interact via an oxime condensation. 
Disadvantages of this reaction are that this reaction was optimal in acidic conditions, 
which is not ideal for biological systems, and the reaction has slower reaction rates than 
other common bioconjugation reactions. However, Dirksen et al. elucidated that aniline, 
or aniline-like molecules, have a nucleophilic catalytic effect.18 This greatly accelerated 
the reaction and allowed it to occur at near physiological conditions, making it highly 
efficient in labeling cells. Ultimately, the incorporation of this functionality into 
biological macromolecules will enable stable and orthogonal conjugation reactions with 
fluorescent probes, cancer drugs, or other molecular tools that contain ketone/aldehyde 
functionalities.   
Scheme 2. 
 
                     
1. III. APPLICATIONS OF BIOCONJUGATION REACTIONS 
  
Incorporation of UAAs and corresponding bioconjugations employing the 
residues creates various unique opportunities for proteins. For instance, profluorophores 
are a class small biomolecules that have fluorescent structures, like conjugated rings and 
conjugated alkyl chains, which are quenched by electron donating or electron 
withdrawing functionalities.20, 21 In the case of azide and alkyne functionalized 
profluorophore molecules, these two chemical handles can undergo a 1,3 dipolar 
cycloaddition to form a triazole ring structure, which delocalizes the electrons in the 
structures and the product subsequently exhibits fluorescence. This represents a very 
useful tool to fluorescently label cells, with very little background noise due to unspecific 
labeling. Since it is already possible to incorporate an alkyne or azide UAA reaction 
partner into proteins, this technology can readily be translated to a protein context.  While 
R O NH2 R
O
Me R
N
Me
O R
+ H2O+
pH 4.0
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several fluorescent UAAs already exist and have been incorporated into proteins, they 
tend to be larger residues and can possibly disrupt a protein’s functionality. Moreover, 
the native fluorescence necessitates the washing away of unincorporated UAA, leading to 
substantial issues as this is difficult to do in a biological system. Utilization of pro-
fluorogenic residues can therefore be used to specifically label cancer cells with 
fluorescent tag without undesired background fluorescence. This can ultimately aid 
surgeons to locate and excise malignant tumors during operations.5 
 Other novel applications of biocongugation technologies include the synthesis of 
specific antibody-drug conjugates.6 Common cancer therapeutics are produced by 
reaction of either cysteine or lysine residues on an antibody with a toxic small molecule. 
Once the antibody is bound to cancer cells it is endocytosed into the cell, degraded, thus 
releasing the cytotoxic cancer drug into the cell. The synthesis of antibodies with UAAs 
allows for greater specificity in the generation of this conjugate, compared to the 
unspecific conjugation methods currently used (Figure 5). 
Antibody conjugates were synthesized by Axup et al. with a UAA incorporated in 
specific residues of the antibody (Figure 5). This UAA possessed a keto group that was 
reacted with a cancer drug that with an alkoxyamine functional group to generate an 
oxime linkage. This methodology allows for specific drug application, as the antibodies 
are only endocytosed in cancer cells, and therefore the drug will only be released into 
cancer cells, decreasing systemic toxicity.  
 
 
Figure 6. Keto group of incorporated UAA that has an alkoxyamine interaction with it to 
form an oxime linkage, from Proc. Natl. Acad. Sci. USA 2012, 109 (40), 16101-6.6 
 
Within the emerging field of synthetic biology UAA technologies have proven to 
be extremely valuable. This subset of biology looks to develop new biological tools that 
will aid in our attempts to begin to understand various life processes and create new 
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functions for organisms. UAAs can play a significant role in the development of these 
tools. For instance, Minaba et al. used UAA introduction into bacterial cells as a signal 
for a translational switch known as an AND switch.7 This switch, when activated by the 
binding of the UAA, will act as a promoter on the gene transcribing the aaRS/tRNA pair 
that will incorporate the UAA (3-Iodo-L-tyrosine) into a protein. Without the presence of 
UAAs in the cell, transcription will cease and eventually the protein will be degraded. 
This was used as a proof of concept that primative translational switches can be designed 
to induce transcription and translation of aaRS/tRNA pairs by the presence of UAAs, 
which allows more specific control of when UAAs will be integrated into the protein of 
more complex organisms. This could lead to improved study of cellular processes in the 
future, as a researcher could expand upon this work and possibly design a control 
mechanism that would not only allow the cellular uptake of a UAA, but also the 
subsequent incorporation into a protein (Figure 7).7 
 
Figure 7- Diagram of the genetic circuit using UAA from Appl. Environ. 
Microbiol. 2014, 80 (5), 1718-25.7 
  
These functions emphasize the vast utility of this technology. With its 
improvement and expansion there is significant of promise in what can continue to come 
in the future. 
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CHAPTER 2: DEVELOPMENT OF ALKOXYAMINE UNNATURAL AMINO 
ACIDS FOR BIOCONJUGATION APPLICATIONS 
2. I. INTRODUCTION 
A commonly exploited bioconjugation reaction involves the reaction of an 
alkoxyamine with a carbonyl moiety to generate a stable oxime linkage. This reaction is 
typically initiated by protonation of the aldehyde/ketone functionality, often requiring a 
slightly acidic environment (pH ranging from 4-6).22-24 Unfortunately, due to the innate 
reactivity of aldehyde UAAs containing these functionalities are difficult to genetically 
incorporate. But in recent work, Tuley et al. incorporated an aldehyde UAA, meta-
formyl-phenylalanine, into protein and labeled it using a hydrazine dye.25 This labeling 
reaction was rapid as compared to reactions with ketones (182 M-1 s-1) at pH 7.25, 26 
Ketone functionalized UAAs are more commonly incorporated into protein and are used 
frequently in studies of oxime ligations. Functionalities like p-acetyl-L-phenylalanine 
(pAcF) possess a ketone functionality, and can readily be incorporated into proteins using 
the pAcFRS to introduce a bioorthogonal handle for these reactions (Figure 8).11 The 
alkoxyamine functionality has yet to be incorporated into protein as an amino acid 
functionality, it is usually a functionality of a non-biological associating molecule. 
There are various advantages and disadvantages to using oxime ligations, creating 
a unique niche of utility within the study of biological conjugation. The primary 
advantage of these reactions includes their overall ability to occur under physiological 
conditions in the presence of special catalysts.22, 27 Moreover, the reaction yields a stable, 
geometrically well-defined, covalent oxime linkage, and unlike many other 
bioconjugations does not rely on cytotoxic transition metal catalysts.28 However, these 
reactions also have disadvantages relative to other bioorthogonal chemistries. The fact 
that the reaction is acid catalyzed, requiring a moderately acidic environment, is 
deleterious for living cells, as protein degradation occurs and other cellular functions may 
be hindered.22 Perhaps even more disadvantageous is the slow reaction rate of the 
ligation.22, 28 With an approximate reaction rate of less than 10-2 M-1s-1 these reactions are 
sluggish and highly pH dependent.23 Using higher concentration of the reactants within 
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the cell has been used to accelerate the reaction, but can lead to toxicity and non-specific 
reactions with molecules in the cell that also have ketone/aldehyde moieties (e.g. 
pyruvate, triglycerides, nucleic acids, acetyl-CoA).22 In order to remedy these slow 
reaction rates, Zeng et al. have shown that the addition of strong nucleophiles, like 
aniline, will effectively accelerate the reaction rate.17 Aniline and similar compounds 
have been demonstrated to act as catalysts that enhance the electrophilicity of the carbon, 
using its conjugated ring system to withdraw electrons, and therefore rendering it more 
susceptible to addition of an alkoxyamine. These additives have been shown to increase 
the reaction rate to 8.2 M-1s-1 in a neutral environment (Scheme 3). 
Scheme 3.  
 
Kim et al. investigated tagging cells using this reaction by reacting p-acetyl-L-
phenylalanine and m-acetyl-L-phenylalanine residues incorporated in the outer membrane 
protein LamB (Figure 8).29 These UAAs were then reacted with fluorescein and biotin 
hydrazides in a site-specific manner. In a separate study, Zeng et al. incorporated a 
diketone containing derivative of phenylalanine in the Lys7 Z-protein domain and labeled 
the protein with an Alexa Fluor 488 hydroxylamine derivative or a hydroxylamine biotin 
derivative.30 The results of these studies indicated that this method of protein tagging is 
highly efficient and site specific. 
 
R1
O
Me R1
O
Me
H Me
NH
R1
O
OR2
H
pH 4-6 H2N
O R -H2O N
R1Me
O
R2
- H
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Figure 8. Ketone functionalized UAAs  
 
 Additionally, these reactions have been applied to label or kill HER2 expressing 
cancer cells31. HER2 oncogenes express membrane receptor proteins that are found in 
breast cancer cells. Bispecific antibodies that allow for the linkage of cancer cells and T-
cells which express membrane receptor protein CD3 using UAAs with biocojugation 
accessable reisdues. The anti-HER2/anti-CD3 bispecific-antibody linkage was effectively 
prepared through the incorporation of pAcF, which interacted with a bifunctional 
ethylene linker. This linker is functionalized with an alkoxyamine residue and an azide or 
alkyne residue to allow for conjugation to a HER2 cell or a T-cell and then linkage of the 
two by Cu(I)-1,3-cycloaddition, allowing for a more directed immune response and 
increased cytotoxicity for HER2 cancer cells with picomolar concentrations of the 
antibody.32 This technology was also employed to create antibody drug conjugates 
(ADC), generating immunoconjugates with cytotoxic molecules to specifically target and 
kill HER2 expressing cancer cells, while significantly reducing off-target cytotoxicity.6 
Finally, oxime methodologies have been employed to detect cancer cells by immuno-
PCR using similar antibody bioconjugates31. These antibodies utilize an oxime 
bioconjugation of an oligonucleotide to the structure of an antibody, which has many 
sites for PCR amplification. These sights are amplified by rolling circular amplification 
using a circular oligonucleotide. Amplification produces short (~20 nt) sequences that 
can then be fluorescently labeled using fluorescently tagged oligonucleotide 
H3N
O-
O
O
p-acetyl-L-phenylalanine
H3N
O-
O
H3N
O-
O
O
O
O
m-β-diketone-L-phenylalanine
m-acetyl-L-phenylalanine
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complements, allowing fluorescent labeling of antibody bound Her2 expressing cancer 
cells (Figure 9).31  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 9: Site-specific immuno-PCR as a method of fluorescently labeling Her2 cancer 
cells, from	Proc.	Natl.	Acad.	Sci.	USA	2012,	109	(10),	3731-6. 
 
Ultimately, in all of these examples, the specificity and bioorthogonality of the 
UAAs have substantially advanced the field and provided novel treatment and detection 
methodologies for cancerous cells. Consequently, further development of the oxime 
ligation to increase physiological compatibility, accelerate reaction rates, and incorporate 
aminoxy functionality into biological systems will only increase the utility of this 
reaction.  
In all of the previously described applications molecules with alkoxyamine 
functionalities have been reacted with protein containing a ketone. An alkoxyamine 
residue has not yet been incorporated into a biological system via unnatural amino acid, 
technologies. This UAA would possess substantial advantages, especially as the 
reactivity can be more highly controlled than the ketone analogs previously employed. 
This moiety can ultimately be used in a bioconjugation reaction with either a ketone or 
aldehyde partner. The incorporation of an aminooxy unnatural amino acid into proteins 
will allow site-specific oxime ligation reactions to occur without the concern of cross-
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reactivity that may occur with more highly reactive aldehyde UAAs. This also facilitates 
bioconjugation reactions with previously synthesized ketone containing amino acids. 
These linkages will result in stable covalent bonds and can be employed in the 
development of new reaction methodologies that are more useful and applicable in 
biological systems.    
In this project, three tyrosine derivatives will be synthesized with alkoxyamine 
functionalities and subsequently incorporated into green fluorescent protein. These 
different unnatural amino acids will possess different numbers of carbon tether lengths 
(2-4 methylene units), which will separate the orthogonal handle from the core of the 
protein. This alteration in reaction distance to the steric hindrance of the protein may 
facilitate more optimal reactions. This has previously been demonstrated with alkynyl 
and azido tethered UAAs, demonstrating a correlation between tether length and 
reactivity.33 This will allow us to optimize reaction conditions to best facilitate its 
interaction with ketones/aldehydes. Through study of these variants we will elucidate 
which structure is optimal for synthesis, incorporation into protein, and formation of 
oxime linkage as an amino acid within a protein.  
2.II. RESULTS AND DISCUSSION 
2.II.A. SYNTHESIS OF UNNATURAL AMINO ACIDS 
 
 To optimize bioconjugation using an alkoxyamine functionalized tyrosine 
derivative, three unnatural amino acids were synthesized with 2, 3, and 4 alkyl chain 
length tethers. These methylene units, extend the functionality from the steric bulk of the 
protein, and may allow for better interaction with a ketone/aldehyde reaction partner.  
These tyrosine derivatives can be synthesized in a two-step process utilizing SN2 
nuecleiophilc substitution reactions (Scheme 4). 
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Scheme 4. 
 
 The synthesis is intitiated with the addition of a brominated alkyl chains to a 
common N-tert-butyloxy (Boc)/OMe protected tyrosine precursor via a substitution 
reaction with dibromoethane, dibromopropane or dibromobutane. This reaction afforded 
tyrosines possessing brominated alkyl chains extending from the para-substituted oxygen 
(1-3). These bromines served as suitable leaving groups for the next step of the synthesis 
involving a substitution reaction of a Boc- protected aminooxy nucleophile.   
 The initial alkyl bromine substitution reactions were based on previous work in 
the Young Lab. A primary issue associated with this synthesis was the propensity to 
under go an elimination reaction instead of one of the SN2 reactions as desired. This was 
especially prevalent in the reactions involving the 2 and 3 carbon tether bromo-tyrosine 
reactions. To prevent elimination and facilitate the desired substitution reaction, catalytic 
amounts of potassium iodide were added to the reaction, which would ideally substitute 
with the bromine, and act as a better leaving group for the desired substitution reaction. 
This modification was not successful as it only yielded unreacted starting materials. In 
another attempt to obtain the desired reaction, a literature search revealed that 
substitution reactions work more efficiently in acetone as a solvent rather than the 
original DMF solvent.34 This modification favored the substitution reaction and 
facilitated the synthesis of all three bromo-tyrosine derivatives. The effectiveness of the 
acetone solvent system was most likely due to the altered polarity of the solution as 
compared to DMF. DMF is more polar providing greater solvent dipole-dipole 
interactions with the bromine, allowing an elimination reaction to proceed. 
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 Based on this previous work, the initial substitution reactions to yield the tethered 
bromides were performed using both potassium iodide as a nucleophilic catalyst, as it can 
replace the bromine and function as a better leaving group for substitution reactions, and 
acetone as a solvent. In these reactions, the majority of the starting material underwent 
the desired SN2 reaction, but some elimination side product was still observed (Scheme 
5). As the alkyl chain length decreased there was an increase in the amount of elimination 
byproducts observed, due to increased stability of the elimination intermediate. We 
hypothesized the elimination was still occurring because the reaction vessel and solvents 
were not anhydrous and polar water molecules were still facilitating an elimination 
reaction. After thorough flame dying of all vials and stir bars the amount of byproduct 
was reduced. The byproduct was then removed via silica flash chromatography and the 
desired bromo-tyrosine (1-3) products were obtained in good to moderate yields and high 
purities.  
Scheme 5. 
 
 
 
 
 
The bromotyrosines (1-3) were then subjected to a subsequent SN2 reaction in 
which the bromine is replaced by a Boc protected aminooxy functionality. Specifically, 
N-Boc Hydoxylamine is dissolved in dichloromethane in the presence of a non-
nucleophilic base 1,8-diazabicycclo-7-undecene (DBU). DBU was employed, as it is a 
weak base that will not remove any protecting groups but will help facilitate the 
hydroxyamic acid to undergo an SN2 reaction. This reaction proceeded as expected and 
the desired products were obtained, with only very small amounts of elimination by-
products. Elimination most likely occurred due to the reduction in chain lengths or use of 
DBU, even though it is a weaker base, the steric interactions of the base may have 
facilitated the elimination. The reaction was then purified using silica flash 
chromatography and the desired products were isolated. 
H
N OMe
O
Boc
O Brn
H
N OMe
O
Boc
O n
n=1,2,3
E2 elimination
	 27	
 While the desired aminooxy functionality was installed, both it and the amino 
acid backbone still harbored protecting groups to prevent undesired chemical reactions in 
the previous steps. A Boc protecting group was used to protect the amino group on the 
backbone as well as the aminooxy functionality and is acid labile. A methyl ester was 
used to protect the carboxylic acid group of the amino acid and is base labile. To remove 
these groups a successive addition of 1M aqueous lithium hydroxide followed by 
neutralization and subsequent treatment with 2% TFA in DCM was performed to yield 4-
6 . The deprotected products (4-6) were then concentrated under vacuum and analyzed 
using 1H and 13C NMR spectroscopy. The overall yields of the final products of this 
protocol are summarized in Table 1. 
Table 1. Overall Yields for the Syntheses of Alkoxyamine UAAs 
 
2.II.B. INCORPORATION OF UNNATURAL AMINO ACIDS 
 
 The newly synthesized alkoxyamine UAAs could then be investigated for 
incorporation into green fluorescence protein (GFP) using the Schultz methodology 
previously discussed (see Chapter 1). Based on previous experiments the surface-exposed 
residue 151 was selected as the site of incorporation and expression of the protein was 
attempted utilizing E. coli. This surface-exposed residue of GFP is an ideal site for 
incorporation as allows for presentation and accessibility of the amino acid residue to 
permit subsequent bioconjugation reactions. It also serves as a useful screening 
mechanism for successful incorporation of the UAA into the protein. This is due to the 
pET-GFP plasmid harboring a stop codon (TAG) at site 151. Thus, the only way 
H3N OH
O
O On NH2
n % Yield
1 (4)
2 (5)
3 (6)
UAA
24.6% (p2AOY)
30.4% (p3AOY)
28.2% (p4AOY)
	 28	
expression will occur is if the tRNA can be charged with the UAA and utilized to 
suppress the stop signal. If the bacteria do not have the mutated synthetase or do not 
properly charge the UAA then translation will halt at the codon, preventing proper GFP 
expression and resulting in an absence of fluorescence 
 In order to charge the UAAs with to the tRNA, an aaRS that at recognizes this 
novel UAA must be identified. An aaRS can either be evolved in a double sieve selection 
(Chapter 1), or the polyspecific nature of certain mutant aaRSs can be exploited. For our 
purposes we will be doing the latter due to the time consuming nature of the selection 
process, and the most effective aaRSs were identified using a fluorescence screen of six 
aaRSs. These 6 aaRSs were selected due to either their previously described promiscuity 
or due to their ability to incorporate structurally similar UAAs to the aminooxy UAAs.11 
Using a microplate reader, E. coli transformed with a pET-GFP-TAG151 and one of the 
pEVOL-aaRS plasmids were expressed with each of the 3 tethered UAAs in triplicate. 
These were then compared to control expressions, which had not received the UAA to 
see which aaRS was the most efficient and able to incorporate each UAA (4-6) (Figure 
10 a-f) 
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Figure 10. Synthetase screen of 4,5, and 6 using the a) pAzF-aaRS, b) pPrF-aaRS, c) 
pCNF-aaRS, d) CouA-aaRS, e) Ambryx-aaRS, and f) Nap-aaRS. 
 
From this screen we identified that the aaRS previously used to incorporate a 
napthalene UAA (Nap) and the aaRS evolved to incorporated a coumarin UAA (CouA) 
were most the most effective at incorporating the four carbon tether alkoxyamine UAA 
(6). We hypothesize these to be effective aaRSs due to their larger binding pocket relative 
to other aaRSs, facilitating the more substantial space requirements of the 4-methylene 
tethered aminooxy UAA.  The para-azidophenylalanine (pAzF) synthetase was the most 
effective at incorporating the three carbon tethered alkoxyamine UAA (5). This is most 
likely due to the structural similarity of the two UAAs and the similar polarities of the 
azide and aminooxy functionalities. Finally, the Ambrx aaRS can incorporate the two 
carbon tether UAA (4), as well as the other two tether length UAAs (5 and 6), with high 
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efficiency. This was expected as this aaRS has been demonstrated to be one of the most 
promiscuious aaRSs known, and has been previously used to incorporate UAAs with 
methylene tethers. These represent exciting results as an aaRS selection is not necessary, 
and as they demonstrate that our newly synthesized aminooxy UAAs can readily be 
incorporated into a protein context. Due to the universality of the Ambryx aaRS for all 
three UAAs, we attempted to utilize it for all future expressions. 
 Having identified viable aaRSs for incorporation in the screen, we next sought to 
confirm these results in more practical expressions that facilitated the isolation and 
purification of the aminooxy-GFP mutatnts. Expressions were performed using the 
Ambryx-aaRS, and the 3 methylene aminooxy UAA (5) was efficiently incorporated into 
GFP. The 2 carbon UAA derivative (4) was incorporated into GFP using the Ambrx –
aaRS effectively as well, but the fluorescence intensity was less than the fluorescence of 
(5), signifying a lower efficiency of incorporation (Figures 11 and 12). Finally, the 4 
carbon UAA (6) did not incorporate as readily as it appeared by the data obtained from 
the synthetase screen. This result prompted some troubleshooting of the expression to 
improve incorporation efficiency.  Early attempts to optimize incorporation of (6) 
attempted to vary several different aspects of the expression. These variables included the 
optical density at induction and the scale of the expressions. Changing these variables did 
not improve the expression yields, so the next variable altered was the aliquot of pEVOL-
aaRS plasmid utilized in the transformations, as previously it had been observed that 
some DNA aliquots had been contaminated. After multiple attempts to transform and 
express the plasmids, expression of (6) in GFP was finally achieved, albeit at low 
expression levels. This is most likely due to the fact that the long tether creates steric 
hindrance in the active site binding pocket of the aaRS. All of the UAA incorporated 
protein was then purified using Ni-NTA affinity chromatography. This afforded the 
immobilization the mutant GFP due to the presence of a 6X histidine tag, which could be 
subsequently eluted into solution with increasing concentration of imidazole. 
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Figure 11. SDS-PAGE gel of (4,5, and 6) mutant GFP-151 protein 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 12. Incorporation efficiency of (4, 5, and 6) into GFP-151 using Ambrx-aaRS 
compared to incorporation of pAzF in GFP-151 using Ambrx-aaRS and a negative 
control. 
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2.II.C. BIOCONJUGATION EXPERIMENTS 
 
Prodan Assay 
  
 Once the alkoxyamine UAAs (4-6) were successfully incorporated into GFP, we 
wanted to assess the ability of each UAA to undergo an oxime ligation with an aldehyde 
or ketone, and ascertain if the variable tether could be utilized to optimize the reaction. 
Our first attempt to create an assay involved the reaction of the UAAs with a prodan dye, 
provided by Dr. Abelt’s lab, which contains a ketone and is a fluorescent molecule. The 
molecule was reacted with the UAA containing GFP and would yield a fluorescent 
product even after the GFP was denatured (Scheme 6). The mutant GFP (100µM) and 
prodan (10 mM) were reacted overnight at 37°C, following a literature protocol from 
Brustad et al., we then purified by size exclusion chromatography, to eliminate excess 
prodan fluorophore.35 The purified protein was then analyzed by SDS-PAGE. During this 
process, the GFP was denatured by the SDS and lost its inherent fluorescence on the gel, 
resulting in the only observable fluorescence arising from the GFP-prodan bioconjugate.  
 
Scheme 6. 
  
Unfortunately, this assay proved to be unsuccessful at assessing the success of the 
oxime ligation. The fluorescence was not a concentrated band were the GFP was found 
but smearing of the fluorescent molecule (Figure 13).  We first suspected that this might 
be due the reaction conditions (pH, concentrations, etc.) not being ideal for this type of 
bioconjugation.   
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Figure 13. SDS-PAGE gel of oxime ligation reactions between (4, 5, and 6) GFP-151 
mutants and prodan. Lanes 6-8 demonstrate successful incorporation of the UAAs into 
GFP-151. Lanes 2-4 show protein was present after the reaction but the reaction did not 
occur as prodan is smeared and unbound as seen on the fluorescence image. 
 
In the literature, reaction conditions that were not suitable for biological systems 
were identified; however, these conditions could be modified to potentially minimize the 
detriment to the protein by reducing the amount of pyridine added, and conduct the 
reaction in an aqueous environment.36 To test this reaction we first used propargyl 
aminooxy and 4-nitro-N-(1,3-diphenyl-1H-pyrazol-5-yl)benzamide (DPAP) which has 
ketone functionalities and reacted it with a propargyl aminooxy derivative (Schemes 7a 
and 7b).  
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Scheme 7a and 7b: 
 
 
 
 
 
 
 
 
 
This reaction was successful, as confirmed by 1H NMR spectroscopy, and we 
therefore adapted this reaction protocol to the UAA incorporated protein and prodan. 
Unfortunately, it still did not result in an oxime ligation between the GFP and the prodan. 
No fluorescence was observed by SDS-PAGE analysis despite the presence of protein 
when stained with coomassie blue. It was then hypothesized that the prodan would not 
react with the UAA because the molecule tends to aggregate with other prodan molecules 
in an aqueous environment. This tendency to aggregate would not allow the alkoxyamine 
and the ketone functionalities to be in close proximity to react, and the unreacted prodan 
was then eliminated during the purification of the protein. Thus, a new assay was 
necessary to assess the effectiveness of the oxime ligation. 
 
Ubiquitin Assay 
 Instead of using fluorescence to determine the success of the oxime ligation we 
began to look for methods where we could perform the reaction with a biological 
macromolecule, like protein or DNA, which would result in a gel shift in a SDS-PAGE 
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due to the addition of a compound of a significant molecular weight. Initially, we hoped 
to utilize a DNA oligonucleotide with a ketone/aldehyde modification, but these are no 
longer commercially available, and would be synthetically challenging to access. The 
next logical strategy involves the coupling of two proteins, while this is challenging due 
to the lack of both ketone/aldehydes and aminooxy groups, we were able to introduce 
them into the proteins using the UAA mutagenesis technology, and already had the 
aminooxy-GFP in hand. Previous attempts in the lab to dimerize GFP have been limited 
due to the size of the protein, so an alternative protein bionconjugation partner was 
investigated. Specifically we aimed couple the UAAs (4-6) that are incorporated into 
GFP with para-acetylphenylalanine (pAcF) incorporated into a small protein called 
ubiquitin. Polymeric chains of ubiquitin perform various signaling processes, and thus are 
very exciting for future experiments in more biologically relevant settings.  For instance, 
ubiquitin chains can promote protein degradation, cell cycle regulation, transcriptional 
regulation, vesicular transport of protein through the cell, and are involved in the 
processing of antigens.37 A ubiquitin plasmid with a TAG mutation at residue 48 was 
provided by Dr. Ashton Cropp from Virginia Commonwealth University. Ubiquitin is a 
8.5 KDa protein that will show corresponding shift in the size of a GFP band, once 
bound, on a SDS-PAGE gel.  
 After obtaining the plasmid from VCU, initial issues arose in the expression of the 
protein as we were having trouble transforming the plasmid and obtaining little yield on 
when finally expressed. Several troubleshooting experiments were attempted, including 
the transformation of the plasmid, the expression protocol, and altering the percentage of 
acrylamide gel (12%). Finally, we were able to express and confirm that we had ubiquitin 
protein containing the pAcF UAA. This mutant ubiquitin was then ready for the 
optimization of the oxime ligation reactions with the previously prepared alkoxyamine 
UAA incorporated GFP (Scheme 8).  
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Scheme 8. 
 
 
 
 Unfortunately, the ligations using this protocol also did not work, as there was no 
shift in the SDS-PAGE gel (Figure 14). This most likely was due to low protein 
concentration minimizing the propensity of the two to encounter each other in the proper 
orientation to facilitate a reaction. It could also be due to unfavorable ratios of the two 
proteins for the ligation reaction to occur. Typically in the literature employs a 5 
equivalents excess of one reactant to the other. Therefore, we were unable to demonstrate 
a successful ligation using the alkoxyamine UAA and future troubleshooting of these 
assays needs to be conducted to ascertain if the coupling is indeed feasible within a 
protein context.    
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Figure 14-Oxime ligation of (4, 5, and 6) mutated GFP-151 and pAcF mutated 
Ubiquitin-48. The bands at 25 kDa are GFP. If the ligation were successful the band 
would shift, as it the ligated proteins would be about 33.5 kDa, would be within the red 
box.  
 
2.III. EXPERIMENTAL 
 
Synthesis of p-Bromo-ethyl-Boc-OMe-Tyrosine (1). A solution of Boc-Tyrosine-OMe 
(0.500 g, 1 eq., 1.69 mmol) was prepared in acetone (7 mL) in a flame-dried vial. To this 
solution, cesium carbonate (1.655 g, 3 eq., 5.08 mmol) was added, followed by the 
addition of 1,2-dibromoethane (292 µL, 2 eq., 3.39 mmol). The reaction was stirred 
overnight at 56 °C, cooled to room temperature, filtered into a round bottom and washed 
with EtOAc. The filtrate was then concentrated in vacuum and further purified using 
flash chromatography (silica gel, gradient of 7:1 hexanes/ethyl acetate for 10 fractions, 
5:1 hexanes/ethyl acetate for 10 fractions, 3:1 hexanes/ethyl acetate for 10 fractions, 1:1 
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hexanes/ ethyl acetate for 10 fractions) to afford a clear oil (0.184 g, 0.46 mmol, 27% 
yield). 1H NMR  (400 MHz, CDCl3): δ 7.00 (d, J=8 Hz, 2H), 6.79 (d, J= 8 Hz, 2H), 4.07 
(q, J=8 Hz, 1H), 3.41 (t, J= 4 Hz, 2H), 3.36 (t, J=8 Hz, 3H) 
  
Synthesis of p-Bromo-propyl-Boc-OMe-Tyrosine (2). A solution of Boc-Tyrosine-
OMe (0.500 g, 1 eq., 1.69 mmol) was prepared in acetone (7 mL) in a flame-dried vial. 
To this solution, cesium carbonate (1.655 g, 3 eq., 5.08 mmol) was added, followed by 
the addition of 1,3-dibromopropane (345 µL, 2 eq., 3.38 mmol). The reaction was stirred 
overnight at 56°C. It was then cooled to room temperature, filtered into a roundbottom 
and washed with ethyl acetate. The filtrate was then concentrated in vacuum and further 
purified using flash chromatography (silica gel, gradient of 7:1 hexanes/ethyl acetate for 
10 fractions, 5:1 hexanes/ethyl acetate for 10 fractions, 3:1 hexanes/ethyl acetate for 10 
fractions) to afford a clear oil (0.504 g, 1.20 mmol, 71% yield). 1H NMR  (400 MHz, 
CDCl3): 6.95 (d, J=8 Hz, 2H), 6.73 (d, 8 Hz, 2H), 3.90 (t, J=8 Hz, 2H), 3.60 (s, 3H), 2.16 
(m, 2H), 1.93 (s, 9H) 
  
 
Synthesis of p-Bromo-butyl-Boc-OMe-Tyrosine (3). A solution of Boc-Tyrosine-OMe 
(0.500 g, 1 eq., 1.69 mmol) was prepared in acetone (7 mL) in a flame-dried vial. To this 
solution, cesium carbonate (1.655 g, 3 eq., 5.08 mmol) was added, followed by the 
addition of 1,4-dibromobutane (404 µL, 2 eq., 3.39 mmol). The reaction was stirred 
overnight at 56°C. It was then cooled to room temperature, filtered into a roundbottom 
and washed with ethyl acetate. The filtrate was then concentrated in vacuum and was 
further purified using flash chromatography (silica gel, gradient of 7:1 hexanes/ethyl 
acetate for 10 fractions, 5:1 hexanes/ethyl acetate for 10 fractions, 3:1 hexanes/ethyl 
acetate for 10 fractions) to afford a clear oil that, once cooled, crashed out as white 
crystal (0.494 g, 1.148 mmol, 68% yield). 1H NMR  (400 MHz, CDCl3): δ 6.99 (d, J=8 
Hz, 2H), 6.76 (d, 8 Hz, 2H), 3.66 (s, 3H), 3.43 (t, 8 Hz, 2H), 1.87 (m, 2H)  
 
Synthesis of p-Alkoxyamine-ethyl-Tyrosine (4). DCM (5 mL) was used to transfer (1) 
(0.184 g, 1 eq., 0.46 mmol) into a flame-dried vial. To this solution, N-Boc-
hydroxylamine  (0.091 g, 1.5 eq., 0.69 mmol) was added, followed by the addition of 1,8-
Diazabicycle-7-Undecene (68 µL, 1 eq., 0.46 mmol). The reaction was stirred for 24 
hours at room temperature, then extracted using DCM and brine, 10 mL of brine and 
three 5 mL washes with DCM. The organic layer was dried magnesium sulfate, filtered, 
and concentrated in vacuum. The product was further purified using flash 
chromatography (silica gel, gradient of 7:1 hexanes/ethyl acetate for 10 fractions, 5:1 
hexanes/ethyl acetate for 10 fractions, 3:1 hexanes/ethyl acetate for 10 fractions, 1:1 
hexanes/ ethyl acetate for 10 fractions) and identified using TLC. This afforded a clear oil 
which was subsequently deprotected. Dioxane (500 µL) and 1 M Lithium hydroxide (500 
µL) were combined and added to a vial containing 4. The reaction was stirred at room 
temperature for 2 hours followed by the removal of dioxane via rotatory evaporation. An 
additional 1 mL of water was added, followed by the dropwise addition of 6 M 
hydrochloric acid until a pH of 4 was obtained. The product was then extracted with ethyl 
acetate into a new vial. The organic layer was then dried with magnesium sulfate and 
then filtered and concentrated in vacuum. Trifluoroacetic acid (2%, 1 mL) was added to 
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the vial on ice. The vial was then stirred at room temperature for 1 hour, and the DCM 
was then removed by rotatory evaporation affording a slightly yellow crystal    (0.100 g, 
0.42 mmol, 24.6% yield). MS (ESI) Expected: 241.11, Actual: 240.11 m/z (M+ + H+), 1H 
NMR  (400 MHz, CD3OD): δ 6.05 (s, 3H), 7.00 (d, 8 Hz, 2H), 6.69 (d, 8 Hz, 2H), 1.30 
(s, 2H). 13C NMR (400 MHz, CD3OD): δ 172.34, 128.40, 112.67, 66.28, 34.88 
 
Synthesis of p-Alkoxyamine-propyl-Tyrosine (5). DCM (5 mL) was used to transfer (2) 
(0.504 g, 1 eq., 1.20 mmol) into a flame-dried vial. To this solution, N-Boc-
hydroxylamine  (0.240 g, 1.5 eq., 1.80 mmol) was added, followed by the addition of 1,8-
Diazabicycle-7-Undecene (180 µL, 1 eq., 1.20 mmol). The reaction was stirred for 24 
hours at room temperature, then extracted using DCM and brine, 10 mL of brine and 
three 5 mL washes with DCM. The organic layer was dried using magnesium sulfate, 
filtered, and concentrated in vacuum. The product was further purified using flash 
chromatography (silica gel, gradient of 7:1 hexanes/ethyl acetate for 10 fractions, 5:1 
hexanes/ethyl acetate for 10 fractions, 3:1 hexanes/ethyl acetate for 10 fractions, 1:1 
hexanes/ ethyl acetate for 10 fractions) and identified using TLC. This afforded a clear oil 
which was subsequently deprotected. Dioxane (500 µL) and 1 M Lithium hydroxide (500 
µL) were combined and added to a vial containing 5. The reaction was stirred at room 
temperature for 2 hours, followed by the removal of dioxane via rotatory evaporation. An 
additional 1 mL of water was added, followed by the dropwise addition of 6 M 
hydrochloric acid until a pH of 4 was obtained. The product was then extracted with ethyl 
acetate into a new vial. The organic layer was then dried with magnesium sulfate and 
then filtered and concentrated in vacuum. Trifluoroacetic acid (2%, 1 mL) was added to 
the vial on ice. The vial was then stirred at room temperature for 1 hour, and the DCM 
was then removed by rotatory evaporation affording a clear oil that formed white crystal 
when cooled. (0.131 g, 0.52 mmol, 30.4% yield). MS (ESI) Expected: 255.13 m/z (M+ + 
H+) Actual: 254.13 m/z (M+ + H+), 1H NMR  (400 MHz, CD3OD): δ 7.00 (d, 8 Hz, 2H), 
6.72 (d, 8 Hz, 2H), 3.94 (t, 8Hz, 2H), 1.87 (s, 2H),13C NMR (400 MHz, CD3OD): δ 
172.30, 131.85, 129.40, 114.35, 66.66, 27.60 
 
Synthesis of p-Alkoxyamine-butyl-Tyrosine (6). DCM (5 mL) was used to transfer (3)  
(0.494 g, 1 eq., 1.15 mmol) into a flame-dried vial. To this solution, N-Boc-
hydroxylamine    (0.229 g, 1.5 eq., 1.72 mmol) was added, followed by the addition of 
1,8-Diazabicycle-7-Undecene (171 µL, 1 eq., 1.15 mmol). The reaction was stirred for 24 
hours at room temperature, then extracted using DCM and brine, 10 mL of brine and 
three 5 mL washes with DCM. The organic layer was dried using magnesium sulfate, 
filtered, and concentrated in vacuum. The product was further purified using flash 
chromatography (silica gel, gradient of 7:1 hexanes/ethyl acetate for 10 fractions, 5:1 
hexanes/ethyl acetate for 10 fractions, 3:1 hexanes/ethyl acetate for 10 fractions, 1:1 
hexanes/ ethyl acetate for 10 fractions) and identified using TLC. This afforded a clear oil 
which was subsequently deprotected. Dioxane (500 µL) and 1 M Lithium hydroxide (500 
µL) were combined and added to a vial containing 5. The reaction was stirred at room 
temperature for 2 hours, followed by the removal of dioxane via rotatory evaporation. An 
additional 1 mL of water was added, followed by the dropwise addition of 6M 
hydrochloric acid until a pH of 4 was obtained. The product was then extracted with ethyl 
acetate into a new vial. The organic layer was then dried with magnesium sulfate and 
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then filtered and concentrated in vacuum. Trifluoroacetic acid (2%, 1 mL) was added to 
the vial on ice. The vial was then stirred at room temperature for 1 hour, and the DCM 
was then removed by rotatory evaporation affording a slightly yellow crystal (0.128 g, 
0.477 mmol, 28.2% yield). MS (ESI) Expected: 269.14, actual: 268.14 m/z (M+ + H+), 1H 
NMR  (400 MHz, CD3OD): 1) δ 7.00 (s, 3H), 6.79 (d, 8 Hz, 2H), 3.85 (m, 2H), 3.64 (m, 
2H), 13C NMR  (400 MHz, CD3OD): δ 172.31, 156.11, 128.17, 112.32, 64.90, 27.65 
 
Synthesis of O-(prop-2-yn-1-yl)hydroxylamine (7): DCM (5 mL) was added to a 
flame-dried vial. To this solution, propargyl bromide (0.375 µL, 1.0 eq., 4.20 mmol) was 
added, followed by the addition of N-Boc-hydroxylamine  (0.840 g, 1.5 eq., 6.31 mmol) 
and 1,8-Diazabicycle-7-Undecene (627 µL, 1 eq., 4.20 mmol). The reaction was stirred 
for 24 hours at room temperature. It was then extracted using DCM and brine, 10 mL of 
brine and three 5 mL washes with DCM. The organic layer was dried using magnesium 
sulfate, filtered, and concentrated in vacuum. The product was further purified using flash 
chromatography (silica gel, gradient of 7:1 hexanes/ethyl acetate for 10 fractions, 5:1 
hexanes/ethyl acetate for 10 fractions, 3:1 hexanes/ethyl acetate for 10 fractions, 1:1 
hexanes/ ethyl acetate for 10 fractions) and identified using TLC. The identified fractions 
were then combined and concentrated down in vacuum, affording a clear oil and was 
subsequently deprotected. Trifluoroacetic acid (2%, 1 mL) was added to the vial on ice. 
The vial was then stirred at room temperature for 1 hour, and the DCM was then removed 
by rotatory evaporation affording a clear oil product (0.207 g, 2.91 mmol, 69.3% yield). 
1H NMR  (400 MHz, CD3OD): δ 3.33 (s, 2H), 2.73 (t, 8 Hz, 1H) 13C NMR  (400 MHz, 
CD3OD): δ 76.27, 73.86, 61.36 
 
General Alexa488-alkoxyamine Reaction, Adapted for alkoxyamine UAA with 
Prodan38: GFP incorporated with (1, 2, or 3) was concentrated down using concentrator 
columns (10k MWCO, Corning Spin-X) and switched to alkoxyamine reaction buffer 
(50mM sodium acetate, 150 mM NaCl, at pH 4.0). The protein was added to a 1.5 mL 
Eppendorf ® tube (20 µL). The solution containing prodan was added to the tube (10 µL) 
and the tube was shaken overnight at room temperature and the conjugation was assessed 
using an SDS-PAGE gel. 
 
General Alexa488-alkoxyamine Reaction, Adapted for alkoxyamine UAA with 
Ubiquitin38: GFP incorporated with (1, 2, or 3) was concentrated down using 
concentrator columns (10k MWCO, Corning Spin-X) and switched to sterile deionized 
water. The protein was concentrated down to about 5 µL of solution in a 1.5 mL 
Eppendorf ® tube under vacuum. The Ubiquitin incorporated with para-
acetylphenylalanine was concentrated with concentrator columns and the solution was 
switched to the alkoxyamine reaction buffer (50 mM sodium acetate, 150 mM NaCl, at 
pH 4.0). The Ubiquitin protein in alkoxyamine reaction buffer was added to the 1.5 mL 
Eppendorf ® tube with concentrated GFP protein. The tube was then shaken overnight at 
room temperature and the conjugation was assessed using an SDS-PAGE gel. 
 
 
General Non-Biological Oxime Ligation Reaction36:  First, methanol (1 mL) and 
pyridine (50 µL) were added to a flame dried vial. To the vial the akynone, specifically 4-
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nitro-N-(1,3-diphenyl-1H-pyrazol-5-yl)benzamide (DPAP), (0.5 equivalents), the 
alkoxyamine, specifically O-(prop-2-yn-1-yl)hydroxylamine, (1.0 equivalent), and 
sodium sulfate (1.0 equivalent) are added then stirred for overnight at room temperature. 
The reaction was run on a TLC. The reaction was diluted with water (5 mL) and then 
extracted with ethyl-acetate (1 mL, 5x). The organic layer was dried with magnesium 
sulfate, filtered, and concentrated in vacuum. The product was purified using flash 
chromatography (silica gel, gradient of 3:1 hexanes/ethyl acetate for 10 fractions, 3:1 
hexanes/ethyl acetate for 10 fractions, 1:3 hexanes/ethyl acetate for 10 fractions), and 
identified using TLC. The identified fractions were combined and concentrated down in 
vacuum. To determine if the reaction using DPAP and O-(prop-2-yn-1-yl)hydroxylamine 
was successful 1H NMR spectroscopy was used to determine if 8 was synthesized. 1H 
NMR  (400 MHz, CD3OD): δ 8.04 (d, 4 Hz, 2H), 8.02 (d, 4 Hz, 2H), 7.61 (d, 4 Hz, 2H), 
7.29 (m, 8H), 3.26 (s, 2H), 2.47 (t, 4 Hz, 1H) 
 
General Non-Biological Oxime Ligation Reaction, Adapted for Biological 
Macromolecules36: To a 1.5 mL Eppendorf ® tube, protein with an incorporated 
alkoxyamine UAA, specifically GFP with 1, 2, and 3, (1.0 equivalent), Sodium sulfate 
(1.0 equivalent), and an alkynone, specifically prodan, (0.5 equivalent) are added. To the 
solution 2 µL of methanol and 2 µL of pyridine were added and shook at room 
temperature overnight. To determine if the reaction was a success, the reaction was then 
concentrated using concentrator spin columns (10k MWCO, Corning Spin-X) and 
switched to PBS buffer, then run on a SDS-PAGE gel. The gel was then imaged for 
fluorescence and then coomassie stain.  
 
 
General GFP Expression: A pET-GFP-TAG variant plasmid (0.5 µL) was 
cotransformed with a pEVOL-ambrx plasmid (0.5 µL) into Escherichia coli BL21(DE3) 
cells using an Eppendorf Eporator™ electroporator. The cells were plated onto Luria-
Bertani (LB) agar plates with chloramphenicol (34 mg/mL) and Ampicillin (100 mg/mL) 
resistance at 37°C overnight. Single colonies that had grown on the plate were then 
inoculated into LB media (2-4 mL) containing both ampicillin and chloramphenicol 
resistance. This culture was grown to turbidity overnight at 37°C and subsequently used 
to inoculate expression cultures (20 mL of LB media, 34 mg/mL of chloramphenicol, and 
50 mg/mL of ampicillin resistance) to an OD600 of 0.1. The cultures are then incubated at 
37°C to grow to an OD600 between 0.6-0.8 and expressions were then centrifuged at 
5,000 rpm for 10 minutes and the supernatant was discarded. The pelleted cells were then 
resuspended in 4 mL of LB media (with 34 mg/mL of chloramphenicol and 100 mg/mL 
of ampicillin resistance). The resuspended cells were subsequently induced with the 
addition of 1, 2, or 3 (40 µL, 100 mM), 20% arabinose (4 µL) and 0.8 mM isopropyl β-D-
1-thiogalactopyranoside (IPTG; 4 µL). The cultures were then shook for 16-20 hours at 
30°C. The cultures were then centrifuged at 5,000 rpm for 10 minutes, the supernatant 
was discarded, and the cell pellet was stored at -80°C for at least 20 minutes. The pellet 
was resuspended using 500 µL of Bugbuster (Novagen) containing lysozyme, and 
incubated at 37°C for 20 minutes. The solution was transferred to an Eppendorf tube and 
centrifuged at 15,000 rpm for 10 minutes, the supernatant was then collected and 
transferred into an equilibrated His-pur Ni-NTA spin column (Qiagen) with nickel resin 
	 42	
(200 µL) and GFP was purified according to manufacturer’s protocol. Purified GFP was 
analyzed by SDS-PAGE (BioRad 10% gels, 150 V, 1.5 hours), and employed with 
further purification depending on the solution required for specific reaction conditions. 
The concentrations were determined using fluorescence measurements.  
 
General Ubiquitin Expression: A pET-ubiqutin-TAG variant plasmid (0.5 µL) was 
cotransformed with a pEVOL-ambrx plasmid (0.5 µL) into Escherichia coli BL21(DE3) 
cells using an Eppendorf Eporator electroporator. The cells were plated onto Luria-
Bertani (LB) agar plates with chloramphenicol (34 mg/mL) and Ampicillin (100 mg/mL) 
resistance at 37°C overnight. Single colonies that had grown on the plate were inoculated 
into LB media (2-4 mL) containing both ampicillin and chloramphenicol resistance. The 
culture was grown to turbidity overnight at 37°C and subsequently used to inoculate 
expression cultures (20 mL of LB media, 34 mg/mL of chloramphenicol, and 50 mg/mL 
of ampicillin resistance) to an OD600 of 0.1. The cultures are then incubated at 37°C to 
grow to an OD600 between 0.6-0.8 and expressions were then centrifuged at 5,000 rpm for 
10 minutes and the supernatant was discarded. The pelleted cells were resuspended in 4 
mL of LB media  (34 mg/mL of chloramphenicol and 100 mg/mL of ampicillin 
resistance). The resuspended cells were subsequently induced through with the addition 
of pAcF (40 µL, 100 mM), 20% arabinose (4 µL) and 0.8 mM isopropyl β-D-1-
thiogalactopyranoside (IPTG; 4 µL). The cultures shook for 16-20 hours at 30°C. The 
cultures were then centrifuged at 5,000 rpm for 10 minutes, the supernatant was 
discarded, and the cell pellet was stored at -80°C for at least 20 minutes. The pellet was 
resuspended using 500 µL of Bugbuster (Novagen) containing lysozyme, and incubated 
at 37°C for 20 minutes. The solution was transferred to an Eppendorf tube and 
centrifuged at 15,000 rpm for 10 minutes, the supernatant was then collected and 
transferred into an equilibrated His-pur Ni-NTA spin column (Qiagen) with nickel resin 
(200 µL) and GFP was purified according to manufacturer’s protocol. Purified GFP was 
analyzed by SDS-PAGE (BioRad 10% gels, 150 V, 1.5 hours), and employed with 
further purification depending on the solution required for a specific reaction.  
 
2.IV. FUTURE DIRECTIONS 
 The oxime ligation is a useful tool for bioconjugation chemistry due to its 
hydrolytic stability and relatively physiological reaction conditions. Future work is 
needed to optimize reaction conditions for protein conjugation. This could include 
manipulation of protein concentrations or the addition of strong nucleophilic catalysts 
such as aniline.17 Once	 optimized,	 these	 bioconjugations	 can	 be	 employed	 in	more	biologically	 relevant	 proteins	 toward	 the	 development	 of	 new	 imaging	 or	chemotherapeutic	reagents.” 
 Currently, there are other UAAs that contain ketone functionalities. These 
carbonyls react well with alkoxyamines, but aldehydes are more efficient coupling 
partners for oxime ligations due to their increased reactivity. However, due to this 
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increased reactivity, aaRS evolution experiments have not found a significant degree of 
success. In order to more efficiently incorporate this moiety and prevent interaction with 
cellular components, work will be done to synthesize and incorporate a photocaged 
aldehyde UAA.  Ideally, upon excitation by a specific wavelength of light, the caging 
group be removed to expose the aldehyde functionality. This amino acid will then be able 
to undergo the oxime reaction (without substantial undesired side reactions) and will 
represent an ideal reaction partner for the already developed alkoxyamine UAA.  
 
2.V. CONCLUSION 
 
 I was able to synthesize three novel alkoxyamine functionalized tyrosine 
derivatives. These unnatural amino acids have different alkyl chain lengths to optimize 
alkyl tether length for bioconjugation reactions. Each of the UAAs were also successfully 
incorporated into green fluorescent protein using a polyspecific aaRS. The incorporation 
of this alkoxyamine functionality allows for new bioorthogonal chemistry reactions that 
can be used for bioconjugation or fluorescent imaging with fluorescent molecules. With 
the synthesis of the alkoxyamine UAAs and their incorporation into protein already 
accomplished, only the optimization of reaction conditions remains as a hurdle to 
utilizing these novel amino acids in a biological setting.  
 
 
 
 
 
 
 
 
 
 
 
 
CHAPTER 3: SYNTHESIS OF PROFLUOROPHORE 2-
ETHYNYLBENZO[d]THIAZOLE AND BIOCONJUGATION IN PROTEIN 
 
3.I. INTRODUCTION 
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 Fluorescent dyes are a class of molecules that are of extremely useful in the 
labeling of biological structures and macromolecules. This biological labeling provides a 
means to study the synthesis and movement of certain biological molecules like protein, 
nucleic acids, carbohydrates or whole cells.21 Fluorescent dyes can also be used as a 
mechanism of studying various biological processes. For instance, fluorescent probes 
have been used to study glycosylation in vivo or specific types of cell using labels of cell 
surface glycoproteins.39 Shieh et al. have also used these probes to label newly 
synthesized DNA and RNA to measure cell proliferation.40 Unfortunately, the fact that 
these molecules are already fluorescent, and are difficult to remove from the system of 
study once introduced, leads to a high amount of background fluorescence when applied 
to a biological system. This background fluorescence of unreacted dyes can sometimes 
significantly complicate results and invalidate experiments. To remedy this, many 
fluorescent probes produce a shift in their emission wavelength once reacted or bound to 
a biomolecule, decreasing undesired signal. Moreover, even though some fluorophores 
experience a shift in the emission wavelength once bound, the use of fluorescent 
molecules that attach to common chemical functionalities found in biological system can 
also facilitate unwanted background labeling.41 These complications result in over-
labeling and mislabeling of biological molecules and additional research is needed to 
address these issues. 
One solution to these complications with biological imaging involves the 
development of small molecules that are non-fluorescent due to quenching effects of 
attached moieties in their unreacted state, but upon reaction become fluorescent.39 These 
functionalities can be either electron donating or electron withdrawing and prevent the 
electronic transitions necessary for fluorescence.20 Therefore, in the unbound/unreacted 
state these probes are non-fluorescent. To restore the fluorogenic nature of these 
molecules they must react with another functionality that results in delocalization of 
electrons allowing the molecules to undergo the electronic transitions and fluoresce. This 
allows for application of these probes without the concern of washing the system of 
unbound probes, as they will not afford background fluorescence.   
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Figure 15- Diagram of profluorophore linkage of an alkyne and azide functionality from 
Org. Lett. 2004, 6 (24), 4603-6.20 
 
The fact that the reactions can be directed via the use of non-endogenous 
chemical functionalities, labeling of specific biomolecules can have a greater degree of 
specificity and efficiency.40 For instance, alkyne and azide functionalities undergo a 
Cu(I)-1,3-cycloaddition reaction that forms a triazole ring structure, effectively 
delocalizing their electrons back into conjugated systems (Figure 15).41 These two 
functionalities are not naturally found in biological systems and are thus considered 
orthogonal. This is ideal as they can be incorporated into biological systems using 
mutated amino acids, nucleic acids, and carbohydrates then can be site specifically 
labeled with a dye possessing a complementary functionality to that in the biomolecule. 
Other then the reaction potentially requiring catalytic amounts of copper that can be 
cytotoxic to the cellular environment, the reaction can readily occur in physiological 
conditions. Thus, the incorporation of unnatural amino acids that contain these 
complementary functionalities to profluorogenic molecules allow for a more efficient 
means of tracking proteins within a biological system.  
 
3.II. RESULTS AND DISCUSSION 
 2-ethynyl[d]benzothiazole is an example of an alkyne functionalized 
profluorophore molecule that can undergo a Cu(I)-1,3-dipolar cycloaddtion with an azide 
functionality. The alkyne functionality is electron withdrawing and diminishes the 
fluorescence of the conjugated ring structure. Upon reaction with an electron donating 
azide group the electrons are delocalized and a fluorescent molecule is generated.  Qi et 
al. synthesized this molecule and demonstrated its ability to undergo this reaction with a 
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single azido functionalized amino acid in solution, not within the structure of a protein, 
demonstrating the profluorphore’s utility in binding with amino acid derivatives.   
 However, the reaction in a protein context creates a greater challenge for 
profluorophores. Proteins are composed of many amino acid residues that interact with 
each other to form secondary, tertiary, and quaternary structures. These structures are 
vital for the proper function of the protein in the cell, but add a level of complexity to 
bioconjugation reactions.  So the work by Qi et al. is important in demonstrating the 
fluorogenic ability of the profluorophore molecule but it does not explore the ability of 
this molecule to react and fluoresce in a biological context. In this work we explore how 
the ability of this profluorophore to react with an incorporated azide UAA in the context 
of a biological macromolecule, specifically a green fluorescent protein.   
 
3.II.A. SYNTHESIS OF 2-ETHYNYLBENZO[d]THIOZOLE 
  
Using the synthetic method developed by Qi et al. the synthesis of 2-
ethynylbenzothiozole was performed (Scheme 9).41  
Scheme 9. 
 
 
 
 
 
 
 
 
 
The first step of the synthesis begins with commercially available 2-
aminobenzo[d]thiazole. This compound is subjected to a diazotization-iodination reaction 
in solution with p-toluenesulfonic acid in acetonitrile (Scheme 10). The first step of the 
reaction is stirred at 0°C for 2 hours, and yields the diaozotization intermediate that is 
now susceptible to substitution by halides, specifically iodine. This is accomplished by 
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the reaction with KI, yielding a brown solid after filtration and purification. This step of 
the overall reaction was worked well and resulted in good product yields of 2-
iodobenzo[d]thiozole (1) (1.40 mmol, 69.9% yield).  
Scheme 10. 
 
 
 
 
 
 
 The 2-iodobenzothiozole product (1) is then subjected to a Sonogashira coupling 
reaction. This cross-coupling reaction uses catalytic amounts of copper iodide and a 
palladium catalyst (Pd(PPh3)2Cl2) to functionalize the benzothiozole with an 
trimethylsilyl protected alkyne (Scheme 11). The product (2) is then extracted and 
purified using silica gel chromatography. Due, to the non-polar nature of the molecule 
and its similarity in polarity of the starting material it was challenging to isolate the 
product using silica flash chromatography. Many of fractions that appeared to have 
product also contained significant impurities from starting material and would be 
subjected to a second column, resulting in significantly diminished yields. 
 
 
 
Scheme 11. 
 
 
 
 
 
 In addition, the literature indicates that the protecting group is removed during the 
silica gel chromatography purification, but this was not observed during my synthesis of 
the compound (Scheme 12). Consequently, tetra-n-butylammonium fluoride (TBAF) was 
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employed to remove the trimethylsilyl group. Unfortunately, the product was too 
challenging to isolate from excess TBAF contamination and other routes were examined 
for deprotection. The next method for removal of trimethylsilyl groups investigated 
involved using potassium carbonate and methanol as reagents. Gratifyingly, this method 
of deprotection seemed to be effective as assessed by NMR spectroscopic analysis. After 
the difficulty separating the product from the starting material and troubleshooting the 
deprotection of the molecule, the yield of (3) was very low (0.06 mmol, 5.46% yield) and 
actual application of the profluorphore was difficult to assess. It is hypothesized that the 
yield was very low because the protected molecule (2) and the deprotected product (3) 
have relatively similar polarities they were hard to separate. They both require very non-
polar solvent systems to enter the mobile phase and it was hard to find a solution that 
would separately elute the two products. Therefore, products would be impure or would 
have reduced yield due to multiple column chromatography purifications in an attempt to 
isolate (3).   
 
Scheme 12.  
 
 
 
 
 
 
 
 
 
 
3.II.B. Cu(I)-1,3-CYCLOADDITION REACTIONS 
 
 With small amounts of 2-ethynylbenzothiazole obtained in the previously 
described synthesis, the product was diluted into a 1 mM solution that was then employed 
in a Cu(I)-1,3-cycloaddition reaction. The compound was reacted with a GFP that has 
been mutated to contain an azide derivatized tryrosine using the Shultz methodology 
previously described. The profluorophore was also reacted with a benzyl azide molecule 
to compare both the biological and chemical reaction. Both reactions were performed 
with their own set of controls to afford an effective assessment of the reaction and the 
generated fluorophore.. The reactions followed the general reaction protocol for Cu(I)-
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1,3-cycloadditions and were reacted overnight at 4°C. The reaction solution of the protein 
was purified and then all of the reactions were diluted to the same concentrations using 
PBS, and their fluorescence was measured. Qi et al. reported excitation of the reacted 
groups at 285nm and emission at 363nm, so we excited at the same wavelength and 
measured the emission from 300nm-600nm. However, we observed no changes in 
fluorescence relative to the control. After, multiple attempts at rescanning and re-diluting 
there was still no change in the fluorescence (Figure 16). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 16. Fluorescence spectrum for a Cu(I)-1,3-dipolar cycloaddition with pAzF 
mutated GFP-151 and 2-ethynylbenzo[d]thizole (3). 
 
3.III. EXPERIMENTAL 
 
Synthesis of 2-Iodobenzo[d]thizole (1)41- To a flame dried vial was added 2-
aminobenzo[d]thiazole (0.300 g, 1 eq., 2.00 mmol) and para-toluenesulfonic acid (p-
TsOH) (1.14 g, 3 eq., 5.99 mmol) in 8.0 mL of acetonitrile. In a separate vial potassium 
iodide (0.862 g, 2.6 eq., 5.19 mmol), sodium nitrite (0.276 g, 2 eq., 3.99 mmol), and 1.19 
mL of water were combined. The two solutions were then mixed into a third flame-dried 
vial with a stir bar at 0°C, and the reaction was stirred for 2 hours on ice. The reaction 
was then warmed to room temperature and stirred overnight. At this point the reaction 
was quenched using water (9 mL), and the pH of the solution was adjusted to a pH of 8-9 
using sodium bicarbonate. Sodium thiosulfate (0.010 g, 0.06 mmol) was added and the 
solution was filtered and collected via büchner filtration. The precipitate was washed 
thoroughly with deionized water to yield a red-brown solid. (0.365 g, 1.40mmol, 69.9% 
yield) 1H NMR  (400 MHz, CD3OD): δ 8.04 (1 H, dd, J1=8Hz, J2=1 Hz), 7.85 (1H, dd, 
J1=8Hz, J2=1Hz), 7.42 (2H, m) 
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Synthesis of 2-ethynylbenzo[d]thiazole (3)41- DCM (2.5 mL) was added to a flame-
dried vial, followed by, 2-iodobenzothiazole (0.300 g, 1eq., 1.15mmol), triethylamine 
(1.12 mL, 7 eq., 8.04 mmol), trimethylsilylalkyne (327 µL, 2 eq., 2.30 mmol), 
PdCl2(PPh3)2 (0.016 g, 0.020eq, 0.023 mmol), and Copper(I)Iodide (0.005 g, 0.0221eq., 
0.0254 mmol). The reaction was then stirred under argon at 65°C for 4 hours. The 
reaction was diluted with EtOAc and then filtered into a round-bottom flask. The solution 
was then concentrated under vacuum to afford a dark brown oil. The oil was then purified 
by flash chromatography (silica gel, 100% hexanes for 10 fractions, 10:1 hexanes/ethyl 
acetate for 10 fractions, 7:1 hexanes/ethyl acetate for 10 fractions, and 5:1 hexanes/ethyl 
acetate for 10 fractions) the product was isolated as a dark brown solid. To remove the 
trimethylsilyl protecting group two pathways were investigated. In the first reaction 
attempted, the protected compound was treated with tetra-n-butylammonium fluoride 
(TBAF) (1 mL per 0.1 g of product) and stirred for 45 minutes, followed by extraction 
using DCM and brine in a separatory funnel. The organic layer was collected, dried using 
magnesium sulfate, filtered and then concentrated in vacuum. Unfortunately, this led to 
significant contamination of the product by TBAF so another deprotection method was 
implemented. This method used the protected alkyne benzothiazole (0.023 g, 1 eq., 0.1 
mmol) and potassium carbonate (0.152 g, 4.5 eq., 1.10 mmol) in a (1 mL)1:1 DCM and 
methanol solution, that was stirred overnight at room temperature. The product purified 
by flash chromatography (silica gel, 100% hexanes for 10 fractions, 10:1 hexanes/ethyl 
acetate, 7:1 hexanes/ethyl acetate for 10 fractions) the product was a brown solid (0.010g, 
0.06mmol, 5.46%) 1H NMR  (400 MHz, CD3OD): δ 8.00 (1H, d, J=8 Hz), 7.86 (1H, d, 
J=8 Hz), 7.41 (2H, m), 3.67 (1H, s)  
 
Biological Cu(I)-1,3-dipolar Cycloaddition Reaction: Click reactions were performed 
on GFP protein containing para-azidophenylalanine (pAzF) in reside 151 or benzyl azide 
in a 1.5 mL Eppendorf® tube. To the reaction tube, the following were added in the 
described order: CuSO4 (2 µL, 50 mM), Tris[(1-benzyl-1-H-1,2,3-triazol-4-
yl)methyl]amine (TBTA) (20 µL, 5 mM), 20µL of pAzF containing GFP in phosphate-
buffered saline (PBS), 2-ethynylbenzo[d]thiazole (10 µL, 1 mM), which contains the 
alkyne functionality, and tris(2-carboxyethyl)phosphine (TCEP) (2 µl, 50 mM). Control 
reactions were performed with 20 µL of the pAzf mutated GFP in PBS or benzyl azide 
and of 2-ethynylbenzo[d]thiazole (10 µL, 1mM)  in the absence the Cu-1,3-dipolar 
cycloaddition catalysts (CuSO4, TBTA, and TCEP) to ensure that successful click 
reactions were not a result of non-specific interactions between the alkyne and azide 
functionalities. The reaction solution was then diluted with PBS to the same volume as 
the actual reactions. All of the reactions were incubated for 10 hours at 4°C. All of the 
reactions involving GFP were transferred to concentrator columns (10k MWCO, Corning 
Spin-X) pre-wet with PBS and spun at maximum speed in a tabletop centrifuge for 2 
minutes. This was repeated with 7 washes (PBS, 500 µL) and the final volume was then 
adjusted with extra spins to bring samples to ~25 µL. The samples were then measured 
for fluorescence using a Perkin Elmer LS 55 luminescence spectrophotometer and 
compared with unreacted starting material. The samples were diluted in PBS then excited 
at 285 nm and emission was measured at 300-600 nm, according to literature.41 
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3.IV. FUTURE DIRECTIONS 
 
 In order to perform more effective Cu(I)-1,3-cycloaddition reactions with 2-
ethynylbenzo[d]thiazole, methods must be optimized for isolation of the compound and 
for the removal of the alkyne protecting group. For compound isolation, solvent systems 
that are used to separate the products from the starting materials need to be investigated. 
Ideally, further fine-tuning to create a better non-polar gradient of solvents may allow for 
a more efficient separation. Another approach that can be implemented while trying to 
improve upon column separation is scaling up the reaction conditions. This would 
produce a greater amount of the product, and even if there was a need for further 
separation, a much larger quantity would facilitate conjugation studies. The 
contamination by the reagents and reduction in yield remove the protecting group was 
detrimental to the overall synthesis of this molecule. Thus, improving upon these 
methods or implementation of novel methods would increase the usable yield of this 
synthesis.  
 Once the small molecule synthesis has been optimized, more efficient, Cu (1)-1,3-
cycloaddion reactions can be performed. In addition to measuring the fluorescence shift 
in the reacted product the reaction can also be assessed using SDS-PAGE gels, to 
determine if the reaction was a success. Increased concentrations of not only the 
profluorophore, but also the azide containing protein would aid in actually facilitating the 
analysis of the reaction. For the chemical molecule control using benzyl azide, increasing 
the reaction volume to then have the ability to isolate the product for NMR analysis 
would also aid in troubleshooting the reaction. 
 Ultimately, other conjugations can also be performed using this functionalized 
profluorophore, like Glaser-Hay reactions, which would also ideally yield fluorescent 
probes. Moreover, reaction with biologically relevant proteins will further demonstrate 
the utility of the reaction. With further improvement of the synthesis of this molecule and 
the optimization of reaction conditions will provide a better understanding of the effects 
of this fluorescent probe on biological macromolecules.  
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3.V. CONCLUSION 
 I was able to synthesize small amounts of an alkyne-functionalized 
benzothiozole. The reduction in the yield occurred during the final steps of the synthesis 
route due to an inability to isolate the product. Unfortunately, click reactions with the 
isolated molecule were unsuccessful as there was no significant change in the 
fluorescence spectrum in the reaction with the protein or with a small molecule, benzyl 
azide. Future work should be performed to improve the reaction yields of this 
profluorophore and more labeling experiments should be performed using Cu(I)-1,3-
cycloadditions as well as other reactions like the Glaser-Hay coupling. Further 
characterization of this molecule in the context of a biological macromolecule will help 
elucidate this profluorophore’s utility within a biological system.  
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CHAPTER 4: MUTAGENESIS OF Cas9 FOR INCORPORATION OF 
UNNATURAL AMINO ACIDS 
 
4.I. INTRODUCTION 
 
 Genome engineering is a field of growing importance in biology and 
biochemistry. One of the most recent and most impactful, developments in genomic 
engineering is the discovery, utilization and modification of the CRISPR Cas9 system. 
The CRISPR Cas9 system is a mechanism of defense found bacteria and archaea against 
viral infection, conferring bacterial immunity.42 Ever since it was discovered in 2002, 
researchers have been working with the system to exploit it as a tool for precise genomic 
modification. From the work that has been done CRISPR Cas9 technology has evolved 
for use in site-specific homologous recombination, DNA cleavage, transcriptional 
activation, and transcriptional repression.42 New modifications are constantly being 
performed to this biological tool to even further increase its utility.  
 There are three types of CRISPR Cas9 systems that have been discovered in 
bacteria and archaea.42 Each type has a similar mechanism for viral DNA cleavage 
(Figure 17). The bacteria or archaea has a genomic CRISPR locus that transcribes a 
single transcript containing a series of repeat sequences with variable sequences that 
correspond to foreign genetic material. This is a form microbial immune memory where 
the bacteria will incorporate sequence, a variable region, from a viral DNA into the 
CRISPR loci and can then be used in targeting.  Following transcription of this CRISPR 
RNA, the RNA undergoes a processing pathway that cleaves the transcript into a 
functional trans-activating RNA (tracrRNA) and 20-nucleotide guide sequence, which 
constitute a CRISPR RNA (crRNA).43 This RNA forms a complex with the Cas9 
endonuclease and allows for complementary binding to the DNA of interest. In addition, 
in order for the Cas9/crRNA complex to complementarily bind to the DNA it must also 
recognize a species-specific 2-4 base pair protospacer adjacent motif (PAM) that is next 
to gene of interest in the target DNA. The dual lobed endonuclease then changes 
conformation once bound to DNA, to bring the two nuclease domains, HNH and RuvC, 
to the DNA.44 These domains cleave both strands of the viral DNA rendering it non-
functional. With the complementary base pairing and PAM recognition, this system is 
very site specific. A study by Bikard et al. found that the Cas9/crRNA complex binding is 
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affected by a few as 2 mismatches in the guide RNA sequence and the target DNA, 
significant reductions in effectiveness were witnessed in Cas9.45 This site specificity and 
effective DNA cleavage make this a effective gene targeting and editing tool. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 17. The overall mechanisms of the three types of CRISPR Cas9 systems, from 
Cell 2014, 159 (3), 647-61.42 
 
 To take advantage of this system, Cas9 proteins and engineered single-guide 
RNAs (sgRNAs), which act as processed tracrRNAs and crRNAs, are incorporated into 
various organisms. A commonly used Cas9 endonuclease is a type I endonuclease from 
S. pyogenes.42 These sgRNA guided Cas9’s are used to induce double strand breaks in 
genomic DNA and subsequent homologous recombination with the addition of short 
double stranded DNA sequences with homologous end regions. Moreover, they have 
been employed to generate controlled DNA damage by inducing double strand breaks 
that are repaired using non-homologous end joining. Other groups like the Doudna lab 
have worked to expand CRISPR Cas9’s genetic engineering utility through mutations of 
the two catalytic domains of the Cas9 protein to inhibit its DNA cleavage properties.43 
These mutations in the RuvC and HNH domains are D10A and H840A, respectively. 
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This mutant Cas9 protein is known as “dead” Cas9 or dCas9. It has been used to site 
specifically bind to double stranded DNA of interest and provides a steric inhibition of 
transcription (figure 18). Further modifications to the dCas9 protein have been made by 
groups like Gilbert et al. to combine transcriptional activator proteins and repressor 
proteins to confer greater site-specific control of expression or repression of genes.46 
Other modifications have also been made to bind green fluorescent protein to Cas9 as a 
mechanism to monitor its function in the cell, and mutations to nuclease domains have 
been done individually to create a Cas9 protein that will induce a single strand break in 
the DNA, called nicking.42  
 
 
Figure 18. Cas9 protein and target DNA complex, from Cell 2014, 159 (3), 647-61.42 
  
 In combination, the site specificity of the CRISPR Cas9 system and their 
broadened applications make this technology a groundbreaking advancement in the field 
of genetic engineering as a whole. With our work we intend to add to the utility of this 
technology through the creating of a novel posttranslational inducible control of the 
activity of the Cas9 protein in its DNA binding and cleavage processes. Work has 
previously been conducted in this area, introducing using small-molecule inducers and 
light induction to the Cas9’s nuclease function.42  
Though small-molecule induction of Cas9 here is a method of gene editing 
function, systemic control of the protein’s function is not specific to a certain region of 
the body. Therefore, gene editing is not specific and occurs throughout the organism.  
With light induced control of the protein there is an additional level of spatial and 
temporal control. There exist unnatural amino acids that have protecting groups that 
block canonical amino acid residues, inhibiting their function, that can be cleaved by 
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irradiation at a defined wavelength. These amino acids are referred known as photocaged 
amino acids. Using photocaged UAAs we intend to create a Cas9 protein that can be 
switched on with irradiation of the residue with a specific wavelength of light. This will 
allow the researcher posttranslational control of genetic modifications. Moreover, it 
facilitates the photo-switching control of transcriptional activation or repression, DNA 
editing, or DNA damage. Adding an additional level of control to the various applications 
of the CRISPR Cas9 system has numerous advantages, which we hope to exploit. 
Scheme 13. 
 
 
 
 
 
 
 
Previous work by Deiters et al. and Arbely et al. have shown that a photocaged 
tyrosine derivative known as o-nitrobenzyl-O-tyrosine (ONBY) can be incorporated and 
used effectively in both bacterial and mammalian systems (Scheme 13).47 Our lab has 
been working with this UAA in other experiments and are currently working on 
optimization of incorporation of these photocaged derivatives of tyrosine into protein.  
This work has been ongoing to optimize expression with this UAA using different 
polyspecific synthetases in order to successfully incorporate the UAA into the Cas9 
protein to finally achieve the photo-controlled Cas9 protein.  
 
4.II. RESULTS AND DISCUSSION 
 
 Many modifications have been engineered into the site-specific endonuclease 
Cas9 to optimize its utility in genetic engineering as a whole. One mutated version of 
Cas9 in particular is of great interest is from the work of Dr. Jennifer Doudna. Her lab 
created a version of Cas9 (dCas9) whose nuclease domains are both catalytically 
inactivated by amino acid substitution, D10A and H840A. This mutant Cas9 is therefore 
useful, in combination with gene regulatory proteins, in binding to specific sites on DNA 
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and either activating or repressing transcription. We hope to expand upon this work, as 
we are interested in substituting UAAs into these mutation sites. We hypothesize that we 
can incorporate a photocaged UAA that will act in a similar manner to the amino acid 
substitutions of the dCas9 mutant. However, when irradiated with a specific wavelength 
of light the protecting group will be removed, exposing an amino acid residue that will 
restore the Cas9 nuclease’s catalytic functionality.  
In addition to synthesizing a dCas9 that can be photo-induced into a catalase 
active Cas9, we are also investigating another amino acid site due to information we 
encountered in the literature.43 Jiang et al. determined that there is a tyrosine residue 
(Y450) that plays an influential role in the binding of the target DNA with the crRNA and 
Cas9.  The tyrosine residue induces a kink in the crRNA between the 15th and 16th base 
pair that causes the bases 11-15 to have a tilted orientation that allows for interaction of 
bases 16-20 of the crRNA with the target DNA. Once the target DNA strand is bound the 
tryrosine then shifts 120° into a non-interactive confirmation (Figure 19). To take 
advantage of this influential amino acid residue, we also have targeted this for 
photocaged UAA incorporation. This would give us light inducible control of any Cas9 
mutant’s binding to a target DNA region. Moreover, we anticipate a higher potential for 
success, as the de-caging event will unmask a tyrosine residue that is present in the wild-
type protein. 
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Figure 19. Amino acid Y450 interaction with crRNA and conformational transition 
between target bound and unbound state, from Am Chem Soc 2012, 134 (29), 11912-5.43 
 
 UAA incorporation into these sites of the Cas9 protein will allow for light 
inducible control of both DNA binding interaction as well as the catalytic activity of the 
nuclease domains. This can afford the spatial control of the Cas9 mutants and lead to 
increased utility of this genetic modifying technology.  
 
4.II.A SITE DIRECTED MUTAGENESIS OF Cas9 PLASMID 
 
Using a Cas9 plasmid with a hexa-His tag (pET-Cas9-6XHis) from the Liu lab at 
MIT we designed primers using the QuickChange® primer design program. We 
specifically designed these sets of primers to introduce TAG mutations at amino acid 
codons on the parent plasmid for residues 10, 450, and 840. Using a high-fidelity 
polymerase specific thermocycling protocol, we conducted a mutagenic PCR based on 
the appropriate melting temperatures of each primer set.  This process repeats 25-35 
times, yielding low concentrations of mutated plasmid. The mutated plasmids at this 
stage are contaminated with original template plasmids that do not harbor the mutation. 
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In order to transform only the desired plasmids the template plasmid needed to be 
specifically degraded, this was accomplished using an endonuclease that recognizes and 
cleaves only methylated DNA (template strands). The mutated plasmids were then 
purified and buffer exchanged using a traditional PCR purification kit modified with a 
deionized water elution step to minimize ionic concentrations for electroporation. 
Following transformation, cells that were able to grow on antibiotic resistant LB plates 
were then inoculated into 2-4 mL of antibiotic containing LB media. The bacteria were 
then grown overnight at 37°C and the turbid cultures were then mini-prepped to obtain 
higher concentrations of mutated plasmids.  
We only performed a site-directed mutagenesis on the amino acid residue 450 
codon. Initially, we had complications getting the site-directed mutagenesis reactions to 
work due to the large size of the Cas9 plasmid, as it is 9,265 base pairs long. The large 
size of this plasmid required more specialized polymerases to minimize the introduction 
of undesired mutations during the lengthy polymerization. Additionally, the PCR 
protocol also required a degree of optimization in the concentration of template that 
required, the duration of each amplification step, and the temperature required for 
annealing the primers to the plasmid.  
After, several attempts to optimize thermocycle protocols and utilizing different 
polymerases, the Kappa HiFi™ polymerase and an optimized version of their protocol 
was used to perform a successful SDM. The PCR product was purified, transformed into 
bacteria, and grown on LB plates. These colonies were then used to successfully 
inoculate a liquid LB culture, which was grown overnight and mini-prepped. We are 
currently awaiting DNA sequencing analysis of the isolated plasmids to truly confirm the 
presence of the TAG mutation; however, colony growth relative to a control (no PCR 
amplification), indicate that the mutagenesis was successful.  
 
4.II.B. INCORPORATION OF UNNATURAL AMINO ACID INTO Cas9 
 
 Once the mutant plasmids were purified using a plasmid purification kit, they 
were co-transformed with the pEVOL-pCNF, the polyspecific tRNA synthetase plasmid. 
The cells were grown overnight on LB plates then inoculated into a 4 mL culture and 
grown to turbidity. This starter culture was then used to inoculate a larger expression 
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culture (20 mL). The culture was then induced at an OD600 of 0.6 with para-
propargylphenylalanine (pPrF) as a test of whether we could incorporate UAAs into the 
protein. We selected this amino acid due to its availability in the laboratory and for its 
potential use in other experiments. Ultimately, once expression conditions are optimized, 
we aim to transition to the caged tyrosine UAA.  
 The success of the expression and protein purification was analyzed by SDS-
PAGE. Unfortunately, the gels did not seem to have the correct protein band 
corresponding to full length Cas9. We hypothesized that this could be due to poor 
expression yield of the large protein by the bacteria or that the SDM was actually 
unsuccessful. Moreover, we noticed that the cultures had a distinct odor that we believe 
was due to contaminated stocks of the UAA pPrF. However, when we repeated the 
expression with newly synthesized pPrF we observed similar results, as no Cas9 protein 
was produced.  
 
 
4.III. EXPERIMENTAL 
 
General SDM protocol using Kappa HiFi™ - Into a Eppendorf tube (0.2 mL) 5x 
Kappa HiFi™ buffer (5 µL), 10 mM dNTPs (0.75 µL), 10 mM forward primer (5’-
CATTTCGGATACCCTAGTATGTAGGCCCCCTCG-3’) (0.75 µL), 10 mM reverse 
primer (5’-CGAGGGGGCCTACATACTAGGGTATCCGAAATG-3’) 0.75µL, and 
plasmid template (5 µL;1 ng/µL), were added to sterile deionized water (12.25 µL). The 
reaction was initiated by the addition of Kappa polymerase (0.5 µL), for a final total 
volume of 25 µL. The reactions were placed in a Biorad iCycler 4.006 Thermocycler 
under the following program: 95°C for 2 min, followed by an amplification cycle of 98°C 
for 30 seconds, 66.5°C for 15 seconds, and 72°C for 4.5 minutes. This cycle was repeated 
30 times followed by a final extension at 72°C for 5 minutes, and then incubation of the 
final product at 4°C. After completion of the PCR, the unmodified template DNA was 
digested with the addition of DpnI (1 µL) and incubated at 37°C for 2 hours, The enzyme 
was then denatured at 80°C for 15 minutes and the reaction was purified using a PCR 
purification kit (Qiagen) and eluted into a deionized water (10 µL) to allow for efficient 
electroporation. The plasmid (1.0 µL) was then transformed into Escherichia coli 
BL21(DE3) cells using an Eppendorf eporator® electroporator. The cells were then 
plated on Luria-Bertani (LB) agar plates with kanamycin (50 mg/mL) and incubated at 
37°C overnight. Single colonies were then selected and inoculated into LB media (2-4 
mL) containing kanamycin. This culture was grown to turbidity and then mini-prepped 
with a DNA purification kit (Qiagen).  
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General Cas9 Expression- A pET-Cas9-6xHis plasmid that has undergone the site-
directed mutagenesis (0.5 µL) was cotransformed with a pEVOL-ambrx plasmid (0.5 µL) 
into Escherichia coli BL21(DE3) cells using an eppendorf eporator electroporator. The 
cells were then plated onto Luria-Bertani (LB) agar plates with chloramphenicol (34 
mg/mL) and kanamycin (50 mg/mL) resistance at 37°C overnight. Single colonies were 
then inoculated into LB media (2-4 mL) containing both ampicillin and chloramphenicol 
resistance. This culture was grown to turbidity overnight at 37°C and subsequently used 
to inoculate expression cultures (20 mL of LB media, 34 mg/mL of chloramphenicol, and 
50 mg/mL of kanamyocin resistance) to an OD600 of 0.1. The cultures are then incubated 
at 37°C to an OD600 between 0.6-0.8 and expressions were then centrifuged at 5,000 rpm 
for 10 minutes and the supernatant was discarded. The pelleted cells were then 
resuspended in 4 mL of LB media (with 34 mg/mL of chloramphenicol and 50 mg/mL of 
kanamyocin resistance). The resuspended cells were subsequently induced through the 
addition of para-propargyl-phenylalanine (pPrF) (40 µL, 100 mM), 20% arabinose (4 µL) 
and 0.8 mM isopropyl β-D-1-thiogalactopyranoside (IPTG; 4 µL). The cultures were then 
incubated for 16-20 hours at 30°C, followed by centrifugation at 5,000 rpm for 10 
minutes, and the cell pellet was stored at -80°C for at least 20 minutes. The pellet was 
then resuspended using 500 µL of Bugbuster (Novagen) containing lysozyme, and 
incubated at 37°C for 20 minutes. The solution was transferred to an Eppendorf tube and 
centrifuged at 15,000 rpm for 10 minutes, the supernatant was then collected and 
transferred into an equilibrated His-pur Ni-NTA spin (Qiagen) column with nickel resin 
(200 µL) and GFP was purified according to manufacturer’s protocol. Purified Cas9 was 
analyzed by SDS-PAGE (BioRad 10% gels, 150 V, 1.5 hours) 
 
4.IV. FUTURE DIRECTIONS 
 
 Future work involves first confirming whether the mutagenesis of the amino acid 
residue 450 was successful in creating a TAG codon. This could include attempts to 
incorporate different UAAs or sending the plasmids to be sequenced to see if we obtained 
the desired mutation. Work will also be done to create new mutations at the other amino 
acid sites on the Cas9 plasmid. Other potential sites of UAA incorporation include the 
incorporation of UAAs that can undergo bioconjugation reactions by incorporations of 
bioorthogonal UAAs on outer residue positions of the Cas9 protein.   
 Once the mutagenesis and Cas9 expression with a photocaged tyrosine derivative 
(ONBY) has been optimized, experiments to determine if functionality of the protein can 
be modulated will be done. There are many different types of assays that can be 
performed to test the function of the protein before and after irradiation. For instance, a 
simple assay protocol is available from New England BioLabs. This is an in vitro assay 
where Cas9 proteins, with a single guide RNA, cleave complementary DNA sequences. 
The DNA fragments can then be analyzed by gel electrophoresis to see if DNA cleavage 
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occurs. More complex assays measuring transcriptional control, possibly of fluorescent 
proteins, can be developed to further characterize new sites of UAA incorporation into 
Cas9 proteins.  
 
4.V. CONCLUSION 
 
 In conclusion, I was able to design primers that will create TAG mutations into a 
Cas9 plasmid in order to introduce UAAs that will control Cas9 function. These primers 
were then employed to attempt to mutagenize a Cas9 plasmid. This mutation seemed to 
be successful as transformation with the plasmid conferred kanamycin resistance. 
However, expression of the protein with UAAs was unsuccessful. Therefore further 
characterization of the mutagenesis by sequence analysis is necessary to determine if the 
mutagenesis was successful or if there are certain expression conditions that need to be 
optimized for proper protein generation. Future work is also being done to optimize the 
incorporation of photocaged UAAs into protein and to explore other sites in the Cas9 
protein for the development of bioconjugation uses such as labeling with fluorescent 
molecules or immobilizing a functional protein onto a solid support. These advances will 
contribute novel applications to the expanding utility of this technology.  
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APPENDIX A: NMR SPECTRA 
CHAPTER 2: 
 
A1. 1H NMR of p-Bromo-ethyl-Boc-OMe-Tyrosine (1)- NMR (400 MHz, CDCl3) 
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A2. 1H NMR of p-Bromo-propyl-Boc-OMe-Tyrosine (2)- NMR (400 MHz, CDCl3) 
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A3. 1H NMR of  p-Bromo-butyl-Boc-OMe-Tyrosine (3)- NMR (400 MHz, CDCl3) 
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A4. 1H NMR of p-Alkoxyamine-ethyl-Tyrosine (4)-NMR (400 MHz, CD3OD) 
 
A5. 13C NMR of p-Alkoxyamine-ethyl-Tyrosine (4)- NMR (400 MHz, CD3OD) 
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A6. 1H NMR of p-Alkoxyamine-propyl-Tyrosine (5)- NMR (400 MHz, CD3OD) 
 
A7. 13C NMR of p-Alkoxyamine-propyl-Tyrosine (5)- NMR (400 MHz, CD3OD) 
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A8. 1H NMR of p-Alkoxyamine-butyl-Tyrosine (6)- NMR (400 MHz, CD3OD) 
 
 
A9. 13C NMR of p-Alkoxyamine-butyl-Tyrosine (6)- NMR (400 MHz, CD3OD) 
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A10. 1H NMR of O-(prop-2-yn-1-yl)hydroxylamine (7)-NMR (400 MHz, CD3OD) 
 
 
 
 
A11. 13C NMR of O-(prop-2-yn-1-yl)hydroxylamine (7)- NMR (400 MHz, CD3OD) 
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A12. 1H NMR of N-(1,3-diphenyl-1H-pyrazol-5-yl)-4-nitro-N'-(prop-2-yn-1-
yloxy)benzimidamide (8)-NMR (400 MHz, CD3OD) 
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CHAPTER 3: 
A13. 1H NMR of 2-Iodobenzo[d]thizole (1)- NMR (400 MHz, CDCl3) 
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A14. 1H NMR of 2-ethynylbenzo[d]thiazole (3)-NMR (400 MHz, CDCl3) 
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APPENDIX B: MASS SPECTRA 
CHAPTER 2: 
 
B1. Mass Spectrum of p-Alkoxyamine-ethyl-Tyrosine (4)- (ESI) m/z (M+ + H+) 
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B2. Mass Spectrum of p-Alkoxyamine-propyl-Tyrosine (5)- (ESI) m/z (M+ + H+) 
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B3. Mass Spectrum of p-Alkoxyamine-butyl-Tyrosine (6)-(ESI) m/z (M+ + H+) 
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APPENDIX C: PRIMER SEQUENCES 
CHAPTER 4: 
 
Cas9 D_10TAG_F 
5’-AAGTACTCCATTGGGCTCTAGATCGGCACAAACAGCGTC-3’ 
 
Cas9 D_10TAG_R 
5’-GACGCTGTTTGTGCCGATCTAGAGCCCAATGGAGTACTT-3’ 
 
Cas9 Y_450TAG_F 
5’-CATTTCGGATACCCTAGTATGTAGGCCCCCTCG-3’ 
 
Cas9 Y_450TAG_R 
5’-CGAGGGGGCCTACATACTAGGGTATCCGAAATG-3’ 
 
Cas9 Y_1265TAG_F 
5’-ACACAAACACTAGCTTGAGATCATCGAGCAAATAAGC-3’ 
 
Cas9 Y_1265TAG_R 
5’-GCTTATTTGCTCGATGATCTCATCAAGCTAGTGTTTGTGT-3’ 
 
dCas9 D_10TAG_F 
5’-CAACTGAATTGGTGCCGATCTACAGGCCGATACTGTATTTTT-3’ 
 
dCas9 D_10TAG_R 
5’-AAAAATACAGTATCGGCCTGTAGATCGGCACCAATTCAGTTG-3’ 
 
dCas9 Y_72TAG_F 
5’-CTTACGACGTGTCTAGCGACGGCGGGC-3’ 
 
dCas9 Y_72TAG_R 
5’-GCCCGCCGTCGCTAGACACGTCGTAAG-3’ 
 
dCas9 Y_450TAG_F 
5’-ACATTTCGTATCCCTTAGTATGTCGGTCCTCTG-3’ 
 
dCas9 Y_450TAG_R 
5’-CCAGAGGACCGACATACTAAGGGATACGAAATGT-3’ 
 
dCas9 Y_1131TAG_F 
5’-GAATCGAAGCCACCCTATTTTTTCGAATCCCAATCTTTTTTG-3’ 
 
dCas9 Y_1131TAG_R 
5’-CAAAAAAGATTGGGATCCGAAAAAATAGGGTGGCTTCGATTC-3’ 
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